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ZUSAMMENFASSUNG 
Typ I Allergie ist eine Überempfindlichkeitsreaktion die ungefähr 25% der 
Bevölkerung betrifft. Die sofortigen Symptome (z.B. allergische Rhinitis, 
Konjunktivitis, Asthma oder Anaphylaxie) sind das Resultat der Freisetzung von 
Entzündungsmediatoren welche durch die Kreuzvernetzung von 
rezeptorgebundenem IgE auf Effektorzellen (z.B. Mastzellen, basophile 
Granulozyten) durch das spezifische Allergen induziert wird.  
Typ I Allergie wird oft mit Medikamenten behandelt welche die allergischen 
Symptome lindern können, allerdings nicht auf die zugrundeliegenden Mechanismen 
abzielen. Die bis jetzt einzige krankheitsmodulierende aber zeitaufwändige 
Behandlung ist die allergenspezifische Immuntherapie (SIT). Im Verlauf der SIT 
werden blockierende IgG Antikörper produziert, und deren Induktion wurde als ein 
Hauptmechanismus für die für die Reduktion der allergischen Entzündung 
beschrieben. Diese IgG Antikörper verhindern die Mastzell- und 
Basophilendegranulation, IgE-vermittelte Allergenpräsentation an T Zellen und IgE 
Produktion durch Kompetition mit IgE um die Allergenbindung.  
Ziel der Arbeit war die Analyse allergenspezifischer Antikörper.  
Dazu wurden zunächst die krankheitsauslösenden IgE Antikörper sowie die durch 
SIT induzierten IgG Antikörper charakterisiert. 
Manuskript 1 zeigt die Analyse von Antikörperantworten spezifisch für rekombinante 
Gräserpollenallergene des Lieschgrases in den Seren von zwei Gruppen von 
Lieschgraspollenallergikern. Die Patienten der ersten Gruppe erhielten eine 
Behandlung subkutane Injektionstherapie (SCIT) mit an Aluminiumhydroxid 
adsorbierten Lieschgraspollenextrakten, die Patienten der zweiten Gruppe nur 
entzündungshemmende Medikamente. Wir zeigen dass nur SCIT aber nicht die 
Behandlung mit entzündungshemmenden Medikamenten allergenspezifische 
blockierende IgG Antikörper induziert die in der Lage sind einen Anstieg in der IgE 
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Produktion zu reduzieren. Weiters berichten wir dass positive Langzeiteffekte mit nur 
einem Durchgang der SCIT nicht erzielt werden können, wir können damit eine 
Periode von mehr als zwei Behandlungszyklen als wichtig für den Langzeiteffekt der 
SIT definieren.  
Manuskript 2 analysiert allergenspezifische IgE Antikörper welche aus einem 
Lieschgraspollenallergiker isoliert worden sind und nun in ein „single chain“ Format 
(ScFv) konvertiert wurden was das Austauschen von schweren und leichten Ketten 
erleichterte. Im Verlauf der B Zell-Entwicklung wird die Diversität von IgE Antikörpern 
in einem analogen Prozess zu den weiteren Antikörperisotypen generiert. Dabei ist 
die zufällige Kombination der schweren und leichten Antikörperketten ein wichtiger 
diversifizierender Faktor neben V(D)J-Rekombination, junktionaler Diversifikation und 
dem Hinzufügen von somatischen Mutationen. Wir untersuchten die Bedeutung der 
schweren und leichten Kette für die Spezifität und Affinität der Antikörper. Es zeigte 
sich, dass die Spezifität in allergenspezifischen IgE Antikörpern hauptsächlich von 
der schweren Kette bestimmt wird und dass verschiedene Kombinationen von 
schweren und leichten Ketten in verschiedenen Affinitäten resultieren können. Dieser 
letztere Aspekt könnte klinische Bedeutung haben und erklären warum verschiedene 
Patienten die gegen das gleiche Allergen sensibilisiert sind mit verschiedener 
Intensität reagieren.  
In Manuskript 3 beschreiben wir letztendlich ein Antikörper „single chain“ Fragment 
(ScFv) spezifisch für ein Hauptallergen aus Lieschgras, Phl p 2. Dieses  Phl p 2-
spezifische ScFv behindert die IgE Bindung von Patienten an das Allergen und 
könnte damit für therapeutische Zwecke zum Einsatz kommen. 
SUMMARY 
Type I allergy represents a hypersensitivity reaction that affects around 25% of the 
population worldwide. The immediate symptoms (e.g. allergic rhinitis, conjunctivitis, 
asthma or anaphylaxis) are the result of an inflammatory mediator release that is 
induced by the cross-linking of receptor-bound IgE on effector cells (e.g. mast cells, 
basophils) via the specific allergen.  
Type I allergy is often treated with drugs that mitigate allergic symptoms but do not 
target the underlying mechanisms. The only disease-modifying but time-consuming 
treatment till now is allergen-specific immunotherapy (SIT). During the course of SIT 
allergen-specific blocking IgG antibodies are produced. These IgG antibodies inhibit 
mast cell and basophil degranulation, IgE-facilitated allergen-presentation to T cells 
and IgE production due to competition with IgE for allergen binding.  
The aim of the thesis was to analyze allergen-specific antibodies.  
At first, disease-eliciting IgE antibodies as well as SIT-induced IgG antibodies were 
characterized.  
Manuscript 1 describes the analysis of antibody responses specific for recombinant 
timothy grass pollen allergens in sera from two groups of timothy grass pollen allergic 
patients. Patients in the first group received one course of subcutaneous injection 
immunotherapy (SCIT) with timothy grass pollen extracts adsorbed to aluminium 
hydroxide and patients in the second group received anti-inflammatory treatment. We 
demonstrate that only SCIT but not anti-inflammatory treatment induced allergen-
specific blocking IgG antibodies that were able to reduce boosts of IgE production. 
Further we report that long-term beneficial effects cannot be obtained with only one 
course of SCIT and thus define that at least two courses of SCIT are required to 
obtain long-term beneficial effects.   
Manuscript 2 analyzes allergen-specific IgE antibodies that have been isolated from 
a timothy grass pollen allergic patient and were then converted into single chain 
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format (ScFv) to be able to generate new heavy and light chain combinations. In the 
course of B cell development diversity in IgE antibodies is created in an analogous 
way to the other antibody isotypes. The random combination of antibody heavy and 
light chains is one important diversity creating factor next to V(D)J-recombination, 
junctional diversity and the addition of somatic mutations. We investigated the 
contribution of heavy and light chains for specificity and affinity by shuffling heavy 
chains with light chains. We report that the specificity in allergen specific IgE is 
determined mainly by the heavy chain and it was found that different heavy chain-
light chain combinations result in different affinities. This latter finding may have 
clinical implication as it may explain why different patients sensitized to the same 
allergens show different sensitivity.  
Finally, in Manuscript 3 we characterize an antibody single chain fragment that would 
be suitable for clinical application. This fragment is directed against one of the major 
timothy grass pollen allergens, Phl p 2, and inhibits patients’ IgE binding to the 
allergen.  
 
INTRODUCTION 
1. Some milestones in allergy research 
  
1906 Clemens von Pirquet creates the term allergy 1.  

1911 Leonard Noon introduces immunotherapy with pollen extracts in hay fever 
patients 2.  
 
1921 Otto Carl W. Prausnitz and Heinz Küstner describe the passive transfer of 
immediate skin reactivity by injection of serum from allergic patients ("reagins") 
3. 
 
1935 Robert A. Cooke describes the development of blocking antibodies in the 
course of immunotherapy 4. 
 
1940 Mary Hewitt Loveless characterizes blocking antibodies 5.  
 
1963 Robin A. Coombs and Philip George Houthem Gell classify hypersensitivity 
reactions 6.  
 
1966 Kimishige and Teruko Ishizaka characterize reagins as IgE 7. 
Hans Bennich and Gunnar Johansson identify myeloma ND as IgE 8, 9.  
 
1988 First successful cloning of allergen-specific cDNA 10, 11.  
 
1991 - 92 First usage of recombinant allergens for in vitro allergy diagnosis 12-14.  
 
1993 - 97 Engineering of recombinant hypoallergens for allergy vaccination 15-19.  
 
1996 First population studies with recombinant allergens 20. 
 
2002 Allergy diagnosis with microarrayed recombinant allergens 21. 
 
2001 - 04 First immunotherapy trial with recombinant hypoallergens 22. 
 
2002 - 05 First immunotherapy trial with recombinant wild-type allergens 23, 24.  
  
 
 
 
 
 
 
 5
INTRODUCTION 
2. The term “Allergy” 
“What we need is a new generalized term, which prejudices nothing but expresses the 
change in condition which an animal experiences after contact with any organic poison, be it 
animate or inanimate… For this general concept of changed reactivity, I propose the term 
Allergy… The term Immunity must be restricted to those processes in which the introduction 
of the foreign substance into the organism causes no clinically evident reaction, where, 
therefore, complete insensitivity exists.1”  
(Clemens von Pirquet 1874-1929) 
 
Clemens von Pirquet was an Austrian paediatrician working at the Paediatric 
Department in Vienna. Together with Bela Schick he observed that some patients 
who received antiserum developed a series of systemic and local symptoms which 
they termed “serum sickness”. Similar findings have been recorded for diphtheria and 
tetanus antisera. Obviously, serotherapy not only produced immunity (protection) but 
also hypersensitivity. Both situations had in common that an external agent induced 
“changed or altered reactivity”. Von Pirquet created the term “Allergy” from the Greek 
allos (“other”) and ergon (“work”) to describe a deviation from the original state. 
Today the definition of allergy is often used synonymously with the more specific IgE-
mediated allergy.  
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3. The Coombs and Gell classification of hypersensitivity reactions 
The classification of type I-IV hypersensitivity reactions described by Coombs and 
Gell 6 in 1963 is in a slightly modified version still in use today since it groups allergic 
reactions according to fundamented pathomechanisms.  
 
 
Figure 1. Type I-IV hypersensitivity reactions 25 
 
3.1. Type I or immediate hypersensitivity reaction 
Type I allergy is a classical IgE-mediated disease affecting around 25% of the 
population worldwide 26, 27. There are several explanations for the worldwide 
epidemic of allergic disease. Increased hygiene conditions lead to decreased 
stimulation of the immune system in critical periods of development 28. Air pollution 
due to urbanization which e.g. leads to high levels of vehicle emissions 29 as well as 
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climate change and global warming 30 also increase the susceptibility to develop 
allergies.  
The ability of allergic individuals compared to non-allergics to produce IgE antibodies 
(i.e., atopic condition) depends also on genetic predisposition 31. In general, the 
personal or familial tendency to produce IgE antibodies has been defined by the term 
“atopy”.  
 
3.1.1. Sensitization 
 
Figure 2. Sensitization 33 
 
Allergic sensitization happens in early childhood and it is the first immune response 
which leads to the development of IgE-mediated allergy 32. It is caused by minute 
amounts of allergens that in principal do not show harmful properties. However, in 
allergic individuals the first allergen contact that happens in the case of respiratory 
allergies on mucosal sites leads to allergen uptake by antigen-presenting cells like 
dendritic cells. Further, allergen-specific TH2 cells are primed that can help to 
activate allergen-specific B cells via T cell-B cell interaction. These B cells induce 
class-switch recombination to IgE under the influence of the TH2 cytokines IL-4 and 
IL-13 as well as secondary signals coming from T cells. Resulting from this 
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sensitization process, allergic patients produce allergen-specific IgE antibodies via 
their plasma cells that have evolved from B cells 33, 34.  
 
3.1.2. The immediate phase reaction 
These IgE antibodies bind to their high affinity receptors FcRI that are situated 
amongst others on mast cells and basophils. A 
repeated contact with the allergen leads to the 
cross-linking of allergen-bound IgE antibodies on 
effector cells. A cascade of following events 
results in the release of preformed inflammatory 
mediators like histamine and leukotrienes that 
elicit within minutes allergic symptoms such as 
rhinitis, conjunctivitis or asthma 33, 34.  
 
Figure 3. Immediate reaction 33 
 
3.1.3. The late phase reaction 
Late phase reactions are described in allergic patients who suffer from chronic 
manifestations of atopy. They are caused by strong activation of allergen-specific T 
cells as well as by eosinophil activation. This occurs after hours to days after allergen 
contact. The whole process is caused by the presentation of allergen to allergen-
specific T cells that are activated, proliferate and produce proinflammatory cytokines 
like IL-4, IL-5 and IL-13. These TH2 cytokines are responsible for the induction of 
tissue eosinophilia and finally the production of inflammatory mediators by 
eosinophils. The participation of IgE may have an enhancing effect in this process as 
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IgE bound to FcεRI or FcεRII on antigen presenting cells is able to ease allergen 
uptake and therefore facilitates allergen presentation to T cells 35.  
 
 
Figure 4. Late phase reaction 33 
 
3.2. Type II or antibody-mediated hypersensitivity reaction 
Type II reactions are mediated by IgG but also IgM antibodies that target cell- or 
matrix-associated antigens. This opsonisation leads to cellular destruction via Fc-
mediated effector mechanisms that include phagocytosis by macrophages or 
neutrophils, complement activation by the classical pathway or antibody-dependent 
cellular cytotoxicity mediated by macrophages and NK cells. The most common 
causes for Type II hypersensitivity reactions are some medications like penicillin, 
cephalosporins, hydrochlorothiazide which become associated with red blood cells or 
platelets 36.  
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3.3. Type III or immune complex-mediated hypersensitivity reaction 
In this reaction, antibodies (IgG) bind soluble antigens thereby forming immune 
complexes that become deposited in tissues where they initiate inflammatory 
reactions. Effector mechanisms are again Fc-mediated and include complement 
activation as well as the activation of FcR+ cells resulting in tissue edema, cell 
recruitment and finally tissue destruction. Examples for Type III reactions comprise 
serum sickness and Arthus reaction 36.   
 
3.4. Type IV or delayed-type hypersensitivity reaction 
Type IV reactions are in contrast to the other three hypersensitivity reactions 
mediated by T cells that are exposed to an antigen during sensitization and develop 
adaptive responses. These reactions can be subdivided into three disease patterns. 
In the classical reaction Th1 cells are activated. They home to the site of antigen 
exposure and there they are stimulated to induce a Th1 response. This leads to 
tissue inflammation mediated primarily by macrophages. Tuberculin skin reaction, 
contact dermatitis or rheumatoid arthritis are examples for classic reactions.  
The second disease pattern is cell-mediated eosinophilic hypersensitivity which was 
already described before in section 3.1.3. 
The third type leads to tissue injury by cytotoxic T lymphocytes that recognize cell-
associated antigens, a prominent example would be graft rejections or contact 
dermatitis 36.  
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4. The mediators of type I allergy 
4.1. The IgE molecule and its receptors 
4.1.1. IgE 
 
4.1.1.1. Historical aspects 
The experiments by Prausnitz and Küstner (1921) 3 demonstrated for the first time 
that there is a blood factor that is able to transfer sensitivity to allergens. More than 
fourty years later (1966) this factor was described by Kimishige and Teruko Ishizaka 
as a novel class of antibody that acts “as a carrier of reaginic activity” 7. At this time, 
Gunnar Johansson and Hans Bennich discovered a myeloma protein (IgND) which 
did not belong to any of the other immunoglobulin classes, and an antiserum 
prepared against it had the same specificity as the anti-IgE prepared by Ishizaka 9. In 
1968 it was agreed to call the new class of protein “IgE” 8.  
 
4.1.1.2. Generation of the IgE repertoire 
The IgE repertoire is formed similar as the other antibody isotypes by a series of 
diversity creating factors. Initially, combinatorial diversity is created by heavy chain 
gene arrangement at chromosome 14. Thereby one family member per V, D and J 
gene family is linked to each other 37. Few studies exist regarding the detailed 
analysis of germ line gene usage in allergen-specific IgE antibodies. They reveal a 
broad usage of VH genes in IgE molecules 38-42.  
Further variability in the IgE repertoire is achieved by junctional diversity that 
happens via the changing of sequences in junctional regions between V, D and J 
genes and by the pairing of antibody heavy and light chains.  
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This random pairing is induced during B cell development via the signalling of the 
pre-B cell receptor which consists of a functional heavy chain paired with a surrogate 
light chain. Signalling results in kappa light chain gene rearrangement on 
chromosome 2 in pre-B cells. The generated kappa light chain binds to the heavy 
chain. If this combination fails, lambda light chain gene rearrangement on 
chromosome 22 is induced. Only if the chains are compatible, a functional 
immunoglobulin is expressed on the cell surface that then undergoes selection 
processes 37. Already from this development process in B cells one could speculate 
that the heavy chain plays a dominant role in a functional antibody molecule. 
Previous studies in human IgE antibodies indicate the importance of the heavy chain 
for the determination of binding specificity 40, 41, 43. On the other hand, allergen-
specific IgE molecules have been described where the same light chain combines 
with different heavy chains and therefore seems to be the specificity determining 
factor 44, 45.  
Manuscript 2 addresses the importance of heavy chain and light chain contribution 
for the determination of binding specificity and binding affinity in allergen-specific 
human IgE antibodies.  
The final step in creating diversity in antibodies is obtained by the introduction of 
somatic mutations into germ line genes 37. in fact, the analysis of allergen-specific 
IgE Fabs revealed a varying degree of somatic mutations in the VH regions 42, 
interestingly these regions remain unchanged in patients after several years of 
allergen exposure 42. 
All B cells first express IgM whereas the VH region is linked to the Cµ gene. Other CH 
genes are arranged downstream on chromosome 14 and can be recombined with the 
expressed VH region in class switch recombination 37. The isotype class switch to 
IgE, a process that is induced via TH  cytokines IL-4 and IL-13 as well as secondary 2
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signals coming from T cells. Some authors believe that this happens in the target 
organs of allergic disease .  46, 47
 
4.1.1.3. Structure of IgE 
The basic structure of the IgE molecule is very similar to that of other antibody 
classes. It consists of two antigen-binding Fab regions and a receptor-binding Fc part 
that in contrast to IgG has no flexible hinge region but an additional constant domain 
(Cε2) in each heavy chain. The antigen-binding sites in the V domain are 
represented by three adjacent hypervariable loops per heavy and light chain that are 
described as complementary determining regions (CDRs). Their DNA sequences are 
very susceptible to allergen-triggered somatic hypermutation as described before 
which leads to affinity maturation and further increases diversity.  
 
4.1.2. IgE receptors 
Two cell surface receptors have been identified. The high affinity receptor FcεRI is 
found amongst others on mast cells and basophils. Cross-linking of FcεRI-bound IgE 
by complex allergens is responsible for the induction of the immediate phase reaction 
in type I allergy. The binding of FcεRI to IgE happens with an affinity (KA) of 1010 M-1, 
which is higher then that of the other antibodies for their receptors 48. FcεRI consists 
of four or three chains on human cells. The form containing four chains is expressed 
on effector cells of allergic responses such as mast cells and basophils 49 and 
comprises an IgE binding α chain (FcεRIα), a β chain signalling subunit (FcεRIβ) and 
two γ chain signalling subunits (FcεRIγ) that exist as a homodimer. Both β and γ 
chains contain immunoreceptor tyrosine-based activation motifs (ITAM) for signal 
transduction 50. While the γ subunits are essential for surface expression and signal 
transduction, the β chain principally acts as amplifier for both functions. The form 
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consisting of three chains lacks the β subunit and is found on antigen-presenting 
cells.  
The second receptor is termed FcεRII or CD23. It may appear as soluble fragments 
(sCD23) which are released from the cell membrane by proteolysis or as membrane-
bound CD23 which belongs to the family of trimeric cell-surface receptor molecules. It 
binds IgE with lower affinity (KA ≈ 108 M-1) than FcεRI and was first identified on B 
cells but was also found on a variety of inflammatory cells and follicular dendritic 
cells. It plays a major role in the induction of allergic late phase reaction as binding of 
loaded IgE to CD23 on antigen-presenting cells may lead to allergen uptake and 
further to the presentation of allergen-derived peptides to allergen-specific CD4+ T 
cells 35 that are responsible for late phase inflammation. 
 
4.1.3. The binding of IgE to its receptors 
 
The binding of IgE to its receptors was studied in great detail. The binding site for 
FcεRI was evaluated using recombinant fragments 51 and by solving the crystal 
structure of the complex between Fcε3-4 and the soluble FcεRI alpha chain 
(sFcεRIα) 52 which revealed that the high affinity receptor binds to both Cε3 domains. 
Further, an NMR study with the Cε2-region and sFcεRIα identifies also a cluster of 
amino acids in the Cε2-region that make contact with the receptor 53. Spectroscopic 
studies in solution revealed that IgE – in free condition or bound to its high affinity 
receptor – has a bent structure 54 in which the Cε2-regions are bent back onto the 
Cε3-regions 55.  
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Figure 5. Schematic representation of IgE binding to the FcεRI 56.  
 
Successful binding but also disengagement requires conformational changes in the 
IgE molecule (in the Cε2 and Cε3 region) and in the high affinity receptor. This may 
be one of the reasons for the remarkably slow dissociation rate of IgE from its high 
affinity receptor, which is at least three orders of magnitude slower than that of IgG 
for its receptor 57.  
 
Figure 6. The conformations of the IgE-Fc fragment. 
Structure of the uncomplexed Fcε3-4 fragment showing the Fcε3 domains in closed 
conformation (left) and in open conformation (right) after binding to the FcεRI alpha chain 56.  
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The complex between CD23 and IgE has not been solved so far with X-ray 
crystallography or NMR. However, a panel of experiments have been performed that 
mapped the binding site in the Cε3 region of IgE 58-60.  
 
4.2. Mast cells 
Mast cells (MC), like other myeloid cells, derive from the bone marrow. They are 
found near blood and lymphatic vessels, nerve fibres and of a range of immune cells. 
In addition to their potential physiological roles (e.g. host defence 61, 62, repair 
mechanisms 63, 64) they are key players in IgE-mediated allergic disease. Human 
mast cells can be divided according to the expression of the proteases into MCT 
(tryptase) and MCTC (tryptase, chymase).  
The best studied activation of MC is induced via the engagement of a multivalent 
allergen to FcεRI-bound IgE which leads to receptor crosslink. This process ends in 
the induction of a signalling cascade which results in two waves of mediator release. 
Initially, insoluble granules and their associated preformed mediators are exocytosed 
within seconds, a process that is known as degranulation. Some mediators such as 
histamine become released immediately; others remain in insoluble particles 
(heparin). Proteases are the most abundant mediators associated with MCs. Beta-
tryptase, the major protease released in this activation process, is described to act as 
a natural mechanism for controlling allergic inflammation as it was shown to cleave 
FcεRI-bound IgE 65. Further, the de novo production of mediators leads to the rapid 
synthesis of prostaglandins and leukotrienes and in a second wave to the expression 
of cytokines and chemokines 66.  
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4.3. Allergens 
4.3.1. General description 
Almost all clinically relevant allergens are soluble proteins or glycoproteins with a 
molecular mass of 5 – 80kDa. IgE responses are therefore initiated in a T cell 
dependent manner 67. A great panel of these protein allergens have been 
characterized in great detail concerning their three-dimensional structure and also 
their biological function 33. An example for the relation of function and allergenic 
activity delivers the major house-dust mite pollen allergen Der p 1. This allergen acts 
as a protease and is able to cleave immune cell-surface structures or to damage 
respiratory epithelial cell layers 68, 69. However, allergens have also other biological 
functions which lack the connection to allergenic activities 67, 70.  
IgE responses can also be induced to carbohydrate moieties. In these cases T cell 
help is provided by peptides that are derived from the protein backbone 71. Although 
carbohydrates are able to bind IgE they are weak inducers of mast cell or basophil 
degranulation 72 and may therefore be defined as “IgE reactive antigens” in contrast 
to “allergens”. IgE reactivity to cross-reactive carbohydrates has been described as a 
problem for allergy diagnosis. In insect venom allergy, the usage of recombinant 
allergens that lack the cross-reactive carbohydrates has been proposed to overcome 
these diagnosis problems 73.  
Mast cell and basophil degranulation is induced by allergens and requires the 
presence of at least two epitopes for IgE binding on the allergen.  More precisely, the 
extent of degranulation depends on the number of epitopes and the levels of specific 
IgE 74. It has already been demonstrated that many important allergens contain 
several different IgE epitopes 75, 76, and clustering of these epitopes on the allergens 
may facilitate receptor crosslink 77.  
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Basically, two types of epitopes have been determined. Epitopes that consist of a 
stretch of amino acids are termed sequential whereas those that include at least two 
different areas of the molecule which need to be brought together belong to the 
conformational type. The epitopes on most allergens are created via their three-
dimensional architecture and are therefore conformational 67. Sequential epitopes in 
allergy are also described, but mainly in food allergens 78-81.  
The three-dimensional structures of allergens are very diverse. Whereas some 
allergens are composed of α-helices (e.g. Phl p 5 82) or β-sheets (e.g. Phl p 2 83), 
others comprise a mix of both structures (e.g. Phl p 1, PDB entry 1N10). Allergens 
can exhibit structural similarities with each other or with human proteins, these 
accounts for the phenomenon of cross-reactivity or autoimmunity 67.  
 
4.3.2. Allergen sources 
Allergic patients from different parts of the world are exposed to different allergen 
sources depending on climate, culture or socioeconomic factors. These allergen 
sources may vary regarding their allergen composition. Whereas e.g. sources from 
birch pollen 84 contain one major allergen that is recognized by the majority of the 
patients, other sources contain multiple different important allergens present in 
varying amounts. The allergenic potential of allergen sources is not only determined 
by the allergen itself but also by the release from the pollen grain. As shown for 
grasses and birch, pollen rupture in moisture and form respiratory particles that 
according to their small size should deposit easily in the human airways 85, 86. The 
release of allergen from the pollen also happens very quickly after direct contact with 
the mucosa 87, 88. After their release it is possible that allergens are bound to certain 
materials like diesel exhaust particles which may act as carriers or may have 
adjuvant activity and thus augment Th2 responses 89, 90. Further, allergen sources 
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have been shown to include other substances like phytoprostanes that promote the 
development of allergic disease 91.  
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5. Allergen-specific immunotherapy 
5.1. General aspects 
Allergen-specific immunotherapy (SIT) is defined as the repeated administration of 
the sensitizing allergen. It is performed by subcutaneous injection (SCIT), and also 
by alternative routes such as sublingual application (SLIT). The first description of 
SIT goes back to 1911 where Leonard Noon performed subcutaneous injection of 
grass pollen extract in order to prevent allergy to grass pollen 2. In larger clinical trials 
performed with John Freeman he reported an improvement in allergic symptoms that 
could be maintained for one year 92. 
SIT is the only causative way of allergy treatment that has a disease-modifying effect 
and induces active immunity 34. It improves the quality of life of treated patients by 
reducing symptoms of allergy and the use of rescue medication. SIT is connected 
with improved tolerance to allergen challenge and it has been described to be long-
lasting. In the case of the subcutaneous administration, clinical effect can be reported 
after three years of discontinuation or even longer 93-96. Long-lasting effects have also 
been described concerning the disease-modifying effect of SCIT like the prevention 
of asthma 97-99. All these effects have been achieved by the performance of a 
treatment protocol that last for three years, however it still needs to be determined 
whether shorter treatment periods would also be beneficial. Therefore, manuscript 1 
addresses this question and analyzes sera from grass pollen allergic patients who 
received one course of SCIT in comparison to sera from patients who received only 
anti-inflammatory treatment. Immunological alterations and resulting clinical 
implications are discussed before and after SCIT and after five years of 
discontinuation 100.  
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5.2. Sublingual versus subcutaneous immunotherapy 
The sublingual administration of allergen (SLIT) has recently been focused as an 
alternative way to the subcutaneous route because it has the advantage of self-
administration. As underlying immunological mechanisms increases of specific IgG, 
and moreover increases of blocking antibodies in patients’ sera are reported 101. The 
effect of SLIT on T cell responses is controversial and ranges from reduced 
proliferation in response to allergen to failure in the detection of changes of T cell 
parameters 102, 103. SLIT further reduces the number of infiltrating inflammatory cells 
like eosinophils and neutrophils 104.  
Although SLIT seems to have some clinical benefits 101, the effects were moderate 
compared to those obtained by subcutaneous administration of allergen preparation.  
 
5.3. From allergen extracts to recombinant allergens and allergen derivatives 
SIT with natural extracts as introduced by Leonard Noon 2 is still performed today but 
has several disadvantages. One of the main problems is that the administration of 
allergen extracts leads to local and systemic side effects 67 (urticaria, asthma shock, 
anaphylactic shock). Therefore, several attempts have been made to increase their 
efficacy and reduce these side effects. Allergen extracts were adsorbed to adjuvants 
in order to immobilize the allergens and increase their immunogenicity 105, extracts 
were chemically modified in order to reduce their allergenic activities 106, 107 or 
different administration routes were considered.  
Another critical point in the usage of allergen extracts is their varying allergen content 
108-111. Therefore, various forms of standardization have been considered in order to 
improve the quality of the extracts like determination of protein contents, assessment 
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of biological activity or antibody-based measurement of allergens. Companies 
marketing allergen extracts for therapy or diagnosis still use different in-house 
methods that are displayed by company-specific units, therefore it is impossible to 
compare products from diverse companies 112.  
Nevertheless, the problem of underrepresentation of certain allergens in the 
preparation still remains 110, 111. Commercial allergen extracts have also been 
described to contain allergens from other sources 113, contaminations with endotoxin, 
114 or other undefined compounds 91. Therefore, the preparation of defined, pure 
proteins as recombinant allergens offers a promising alternative.  
Since 1988 10, 11, a lot of effort has been put into the recombinant expression of 
allergens from varying sources, and today recombinant allergens for the most 
important allergen sources have become available 115. With these tools the reactivity 
profiles from allergic patients can be determined by component-resolved diagnosis, 
and the disease-eliciting allergen molecules can be identified 116. Consequently, 
patients can be selected more efficiently for immunotherapy. The monitoring of 
antibody responses in allergic patients has greatly been facilitated by the introduction 
of multi-allergen test systems based on micro-array technology 21.  
Basing on recombinant DNA technology it is possible not only to work with pure 
allergens showing the same characteristics as their natural counterparts, but also to 
modify the molecules in order to obtain hypoallergenic variants with reduced IgE 
reactivity. The first generation of variants was made to preserve allergen-specific T 
cell epitopes and induce allergen-specific IgG that inhibit IgE recognition 117. 
Therefore, strategies have been developed that succeed in the destruction of 
conformational IgE epitopes. These include fragmentation 18, denaturation of the 
recombinant wild-type allergen (folding variant) 118 or recombination of allergen 
fragments to form mosaic molecules 119. Site-directed mutagenesis may also be used 
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to reduce IgE reactivity 17 and is has been found that recombinant oligomerization of 
allergens results in the loss of allergenicity by altered presentation of IgE epitopes 
although IgE reactivity could be preserved 120. 
Today, another strategy arises with the aim to eliminate IgE- or T cell-mediated side-
effects. This approach is based on allergen-derived peptides that originate from 
conformational IgE binding sites of the allergen and lack IgE reactivity and are fused 
with nonallergen-derived carrier proteins (e.g. viral proteins). These vaccines focus 
on the production of IgG antibodies directed against IgE binding sites without 
activating allergen-specific T cells as T cell help is provided by the epitopes on the 
carrier protein 121, 122.   
 
 
Figure 7. Generation of hypoallergenic variants 117.  
 
The first immunotherapy trials that were performed in allergic patients were 
interestingly conducted with recombinant hypoallergenic allergen derivatives 22 and 
then continued with a recombinant hypoallergenic folding variant 118 of the major 
birch pollen allergen, Bet v 1. Beside these trials, alternative approaches were 
 24
INTRODUCTION 
started that used recombinant wild-type allergens for administration to allergic 
patients 23, 24. All of these trials showed successful outcomes in terms of 
immunological and clinical parameters.  
 
5.4. Effects of allergen-specific immunotherapy 
 
 
Figure 8. Effects of allergen-specific immunotherapy on clinical and experimental immune 
parameters 34.  
 
The underlying mechanisms in SIT seem to be diverse and besides induction of 
allergen-specific blocking IgG may include effects on antigen presenting cells, T cells 
and B cells 34.  
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5.5. Blocking antibodies 
It was already demonstrated in 1935 by experiments from Robert A. Cooke that SIT-
treated patients develop allergen-specific factors that prevent immediate allergic skin 
inflammation 4. These factors were then reported to belong to the IgG class and to 
bind to the very same allergen thereby preventing the binding of the sensitizing 
antibody 5, 123 and thus were termed „blocking antibodies“.  
However, not every IgG is a blocking one and therefore the induction of IgG in the 
course of an immunotherapy trial is no sufficient parameter to evaluate the trial 
outcome. Former studies tried to correlate serum IgG concentrations with a positive 
clinical outcome and came to different conclusions 124, 125. 
In general, the SIT-induced IgG response is described as very heterogeneous 
concerning epitope specificity. To show a blocking effect, IgG has to be directed 
directly to the very same epitope as IgE thereby competing with IgE for allergen 
binding or IgG has to bind in close vicinity of the IgE epitope to hamper IgE binding 
via steric hindrance. IgG directed against other epitopes may fail to inhibit IgE binding 
and it has even been reported that IgG enhances binding of IgE to the allergen 
maybe due to the induction of conformational changes in the allergen 126, 127.  
5.6. Mechanisms of allergen-specific blocking antibodies 
1. 2.
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Figure 9. Three different modes of action for allergen-specific blocking IgG antibodies 128.  
 
Allergen-specific blocking IgG antibodies have been shown to operate in different 
ways. They inhibit allergen-induced mast cell and basophil activation which result in 
reduced immediate phase reactions (Figure 9A) 128. There are several clinical trials 
which show that SIT-induced IgG were able to suppress immediate allergic 
inflammation 22-24. It was further shown that SIT induces IgG mainly of the subclasses 
IgG1 and IgG4 that were directed against new epitopes 129, 130 and that were able to 
block IgE binding and further cross-react with structurally related allergens 22, 130.  
Moreover, blocking IgG antibodies inhibit IgE-facilitated allergen presentation of 
antigen presenting cells (APC) to T cells 131, 132 (Figure 9B). This results in the 
decreased activation of T cells that play a crucial role on the one hand in the 
INTRODUCTION 
induction and maintenance of allergic disease and on the other hand in late phase 
responses.  
Finally, blocking IgG can suppress the boost of memory IgE production induced by 
allergen contact (Figure 9C) 22, 133, 134.  
 
5.7. Allergen-specific blocking antibodies for allergy treatment 
As blocking IgG show a central role in the treatment of allergic inflammation they may 
be used for passive immunization 128. Today, techniques and materials for the 
isolation and construction of allergen-specific therapeutic IgG are available. 
Hybridoma technology 135, combinatorial cloning and phage display 136-138 in 
combination with the now existing clinically relevant major purified allergens that are 
used for isolation 139, 140 have enabled the generation of allergen-specific recombinant 
antibodies. Therapeutic IgG would be especially suitable for the treatment of 
seasonal allergies like grass or tree pollen allergies due to their long serum half life of 
approximately 21 days. An example for a possible allergen-specific therapeutic IgG is 
the already described anti-Phl p 2 IgG1. This antibody has been isolated from a 
combinatorial IgE Fab library and was converted into a whole IgG1. It is directed 
against one of the major timothy grass pollen allergens, Phl p 2 43, 141. In manuscript 
3 we suggest a variant of this antibody for topical application. Therefore, an easy to 
produce single chain version of anti-Phl p 2 IgG1 with low immunogenicity was 
constructed and characterized. It inhibited the binding of patients’ IgE to the allergen 
and could therefore be a suitable tool for clinical application. 
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AIM OF THE THESIS AND DECLARATION OF CONTRIBUTION 
Type I allergy represents a hypersensitivity reaction that affects around 25% of the 
population worldwide. The immediate symptoms are the result of an inflammatory 
mediator release induced by the cross-linking of receptor-bound IgE on effector cells 
by the specific allergen.  
The only disease-modifying but time-consuming treatment till now is allergen-specific 
immunotherapy (SIT). During the course of SIT allergen-specific blocking IgG 
antibodies are produced which act by inhibiting mast cell and basophil degranulation, 
IgE-facilitated allergen-presentation to T cells and IgE production due to competing 
with IgE for allergen binding.  
The aim of the thesis was the analysis of allergen-specific antibodies.  
At first, manuscript 1 describes allergen-specific IgE- as well as SIT-induced IgG 
antibodies. In an observational study we show the dissection of antibody responses 
specific for recombinant timothy grass pollen allergens in sera from two groups of 
timothy grass pollen allergic patients. Patients in the first group received one course 
of subcutaneous injection immunotherapy (SCIT) with timothy grass pollen extracts 
adsorbed to aluminium hydroxide whereas patients in the second group received 
anti-inflammatory treatment. We demonstrate that allergen-specific blocking IgG 
antibodies that were able to reduce boosts of IgE production were only induced 
during SCIT but not during anti-inflammatory treatment. Further we report that long-
term beneficial effects cannot be obtained with only one course of SCIT.   
Next, manuscript 2 analyzes allergen-specific IgE antibodies that have been isolated 
from a timothy grass pollen allergic patient by combinatorial cloning and were then 
converted into single chain format (ScFv) to be able to generate new heavy and light 
chain combinations. We investigated the contribution of heavy and light chains for 
specificity and affinity by shuffling heavy chains with light chains. We show that the 
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specificity in allergen specific IgE is determined mainly by the heavy chain and that 
different heavy chain-light chain combinations result in different affinities.  
Finally, in Manuscript 3 we characterize an antibody single chain fragment that is 
directed against one of the major timothy grass pollen allergens, Phl p 2, and would 
be suitable for clinical application.  
 
Manuscript 1 
Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig 
K, Swoboda I, Flicker S, Valenta R. Recombinant allergen-based monitoring of 
antibody responses during injection grass pollen immunotherapy and after 5 
years of discontinuation. Allergy. 2011;66:1174-1182.  
 
Manuscript 1 describes an observational study where sera from two groups of grass 
pollen allergic patients were analyzed. The first group received one course of 
subcutaneous injection immunotherapy (SCIT) with timothy grass pollen extracts 
adsorbed to aluminium hydroxide while the second group obtained anti-inflammatory 
treatment. Sera were analyzed before and directly after treatment as well as after five 
years of discontinuation for IgG1-4, IgA, IgM, IgE and kappa and lambda light chain 
responses to a panel of recombinant timothy grass pollen allergens. We report an 
induction of IgG1>IgG4>IgG2>IgA specific for the major timothy grass pollen 
allergens, an inhibition of allergen-induced basophil degranulation only with sera that 
contain therapy-induced IgG, and further a reduction of IgE levels as well as a 
reduction of symptom and medication scores in the SCIT group after one course of 
immunotherapy but not in the group of patients who received anti-inflammatory 
treatment. After five years of treatment, antibody levels had returned to baseline 
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levels and there was no difference anymore in the SCIT and anti-inflammatory group 
regarding symptoms and medication.  
 
Contribution to Manuscript 1:  
ELISA measurements of IgG1-4, IgA and IgM antibodies and of kappa and lambda 
light chains specific for a panel of recombinant allergens (Phl p 1, Phl p 2, Phl p 5, 
Phl p 6, Phl p 7, Phl p 12, Phl p 13), quantitative RAST-based non-denaturing dot 
blot assay for the determination of IgE reactivity to the same panel of allergens, 
analyzes of the data, writing of the manuscript. 
 
Manuscript 2 
Gadermaier E, Flicker S, Lupinek C, Steinberger P, Valenta R. Determination of 
allergen-specificity by heavy chains in grass pollen allergen-specific IgE 
antibodies. J Allergy Clin Immunol. In revision.  
 
Manuscript 2 describes the conversion of human IgE Fabs which have been isolated 
from a timothy grass pollen allergic patient via combinatorial cloning and which are 
specific for the three non-cross reactive major timothy grass pollen allergens Phl p 1, 
Phl p 2 and Phl p 5 into single chain format (ScFv). Additionally, the heavy chains 
specific for one allergen were recombined with light chains specific for another 
allergen resulting in shuffled ScFvs. Possible ancestor genes for the heavy and light 
chain variable genes were determined and the recombinant ScFv representing the 
original combinations of heavy and light chains as isolated from the combinatorial 
library as well as the shuffled ScFvs were analyzed for binding specificities and 
affinities. We report that promiscuous pairing between heavy and light chains is 
possible and that binding specificity to the allergen the heavy chain is directed to can 
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be maintained. Therefore, the heavy chain plays a dominant role in allergen-specific 
human IgE antibodies in the determination of binding specificity. Further, different 
heavy and light chain combinations result in different binding affinities to the 
corresponding allergen which may explain different clinical reactivities in patients 
sensitized to the same allergens.  
 
Contribution to Manuscript 2:  
Determination and mapping of possible ancestor genes for Phl p 1, Phl p 2 and Phl p 
5-specific human IgE Fabs, multiple sequence alignments of light chain protein 
sequences, conversion of Fabs into ScFvs and shuffling of light chains, expression of 
all recombinant ScFvs, determination of binding specificities in ELISA, affinity 
measurements and evaluations using BIAcore technology, analysis of the data, 
writing of the manuscript.  
 
Manuscript 3 
Gadermaier E, Flicker S, Blatt K, Valent P, Valenta R. A single chain fragment 
specific for group 2 grass pollen allergens with therapeutic potential. Submitted 
 
Manuscript 3 describes the expression and characterization of an allergen-specific 
ScFv fragment. We show that this ScFv binds in a very stable way to the major 
timothy grass pollen allergen Phl p 2 and blocks the binding of patients’ IgE to Phl p 
2. Further, the ScFv inhibits allergen-induced basophil activation. This recombinant 
ScFv fragment may be used for therapeutic purposes.  
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Contribution to Manuscript 3: 
Cloning and expression of the Phl p 2-specific ScFv, determination of association 
and dissociation rate constants and evaluation using BIAcore technology, analysis of 
the potential to inhibit the binding of allergic patients’ IgE in ELISA, evaluation of the 
data, writing the manuscript.  
 
Manuscript 4 
Flicker S, Gadermaier E, Madritsch C, Valenta R. Passive Immunization with 
Allergen-Specific Antibodies. Curr Top Microbiol Immunol. 2011;141-159.  
 
Manuscript 4 reviews the current knowledge of allergen-specific IgG antibodies that 
are induced in the course of allergen-specific immunotherapy and play a major part in 
the reduction of allergic inflammation. The article summarizes mechanisms of action 
as well as engineering strategies of allergen-specific antibodies and antibody 
fragments and discusses applications for treatment and prophylaxis of allergy.  
 
Contribution to Manuscript 4: 
Creation of figures and tables, proofreading of the manuscript.  
 
Manuscript 5 
Gadermaier E. In Shape – The Art of Mapping Conformational Epitopes. Int Arch 
Allergy Immunol. 2012;157:321-322.  
 
Manuscript 5 is an Editorial reviewing the current possibilities to map conformational 
epitopes. These play an important role in type I allergy as the huge majority of 
allergens contain conformational epitopes that are recognized by IgE. It is of great 
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importance to better understand the interface between IgE and the corresponding 
allergen in order to gain more knowledge about the elicited immune responses and 
further to design effective active and passive treatment strategies. The manuscript 
discusses these issues on the basis of a recently published article by Tiwari et al. (Int 
Arch Allergy Immunol. 2012;157:323-330) that reports the mapping of a 
conformational epitope on the major cockroach allergen Bla g 2.  
 
Contribution to Manuscript 5: 
Review of the article by Tiwari et al. (Int Arch Allergy Immunol. 2012;157:323-30), 
writing of the editorial.  
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Subcutaneous injection immunotherapy (SCIT) is considered
as antigen-speciﬁc, disease-modifying treatment for IgE-
mediated allergies (1). It is accompanied by alterations in the
humoral and cellular allergen-speciﬁc immune response which
are thought to reduce allergen-speciﬁc hypersensitivity lead-
ing to tolerance. Subcutaneous injection immunotherapy has
been reported to have long-lasting clinical effects which can be
detected for 5 years and even longer after discontinuation of
treatment. In this context, it has been reported that patients
having received venom immunotherapy for at least 3 years
tolerated stings even after 5 years without treatment (2, 3).
Similar ﬁndings have been made for grass pollen injection
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Abstract
Background: Subcutaneous injection immunotherapy (SCIT) is considered as anti-
gen-speciﬁc and disease-modifying treatment with long-lasting effect.
Methods: We used a panel of recombinant grass pollen allergens for analyzing aller-
gen-speciﬁc IgE, IgG1-IgG4, IgM, IgA, and light-chain (kappa, lambda) responses
in grass pollen–allergic patients who had received one course of injection immuno-
therapy (SCIT) with an aluminum hydroxide-adsorbed grass pollen extract or only
anti-inﬂammatory treatment. Serum samples were analyzed before and after
5 months of treatment as well as after 5 years.
Results: After 5 months of SCIT but not of anti-inﬂammatory treatment, IgG1 >
IgG4 > IgG2 > IgA antibody responses using both kappa and lambda light chains
speciﬁc for major grass pollen allergens (Phl p 1, Phl p 5, Phl p 6, Phl p 2) increased
signiﬁcantly, whereas speciﬁc IgM or IgG3 levels were unaltered. Allergen-dependent
basophil degranulation was only inhibited with SCIT sera containing therapy-
induced allergen-speciﬁc IgG antibodies. Likewise, decreases in Phl p 1- and Phl p
5-speciﬁc IgE levels and signiﬁcant (P < 0.001) reduction in symptom and medica-
tion scores were found only in the SCIT group but not in the group of patients
receiving anti-inﬂammatory treatment. After 5 years, allergen-speciﬁc IgG antibody
levels in the SCIT group had returned to baseline levels and there was no signiﬁcant
difference regarding symptoms between the SCIT and non-SCIT groups.
Conclusion: The results from our observational study demonstrate that only SCIT
but not anti-inﬂammatory treatment induces allergen-speciﬁc IgG and reduces
boosts of allergen-speciﬁc IgE production but that one SCIT course was not sufﬁ-
cient to achieve long-term immunological and clinical effects.
Allergy
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immunotherapy. It could be demonstrated that SCIT for 3 to
4 years induced prolonged clinical remission for at least 3 years
after discontinuation of injections (4). In an independent study,
Eng et al. described a signiﬁcant clinical beneﬁt 6 years after
discontinuation of 3 years of preseasonal grass pollen injection
immunotherapy (5).
Long-lasting effects have been also described for the dis-
ease-modifying potential of SCIT, in particular for the pre-
vention of asthma in patients suffering from allergic
rhinoconjunctivitis in the PAT study (6). A preventive effect
for the development of asthma was also observed in follow-
ups of the PAT study conducted after 5 and 10 years (7, 8).
Although several studies have demonstrated long-lasting clin-
ical effects of SCIT, several important questions remain open.
For example, it has not been investigated whether long-last-
ing effects can be achieved when SCIT is performed for
shorter periods than 3 years and whether such effects may
even be observed after one course of treatment. Furthermore,
only few studies demonstrating long-lasting effects have ana-
lyzed immunological alterations that might be associated or
responsible for the long-lasting clinical effects. The studies by
Golden and Lerch have shown for venom SCIT that long-
term protection was associated with decreases in allergen-spe-
ciﬁc IgE levels and skin sensitivity, whereas allergen-speciﬁc
IgG levels had declined after treatment (2, 3). Similar results
were obtained by Durham et al., who found trends toward
decreases in immediate-type allergen-speciﬁc conjunctival sen-
sitivity, a reduction in late-phase skin responses, and reduced
activation of Th2 cells in biopsies taken from allergen-chal-
lenged skin (4).
We performed an observational study in a group of
patients who had received only one course of preseasonal
grass pollen injection immunotherapy and in a group of
patients who had received only anti-inﬂammatory pharmaco-
therapy. Symptoms and medication were recorded before
treatment, shortly after treatment, and 5 years after the single
preseasonal SCIT course. Furthermore, we performed a
detailed analysis of allergen-speciﬁc antibody responses using
a panel of recombinant allergens at the same time points.
Materials and methods
Recombinant allergens
Recombinant allergens, i.e., rPhl p 1, rPhl p 2, rPhl p 5, rPhl
p 6, rPhl p 7 (timothy grass pollen), and rBet v 1 (birch pol-
len), were purchased from Biomay (Vienna, Austria), and
rPhl p 12 and rPhl p 13 (timothy grass pollen) were puriﬁed
as described (9, 10).
Patients, blood samples, treatment, and monitoring of clinical
effects
Measurements of allergen-speciﬁc antibody responses were
taken in grass pollen–allergic patients (n = 19) who had been
recruited in summer 1999.
The diagnosis of grass pollen allergy in all 19 patients was
based on case history, speciﬁc IgE measurements, and positive
skin prick test results. Twelve patients suffered for more than
2 years from allergic rhinoconjunctivitis (one of them from
concomitant asthma) and had no contraindications for subcu-
taneous immunotherapy (SCIT). These patients agreed to
receive immunotherapy by subcutaneous injections of a mix of
timothy and orchard grass pollen extracts adsorbed to alumi-
num hydroxide gel (Allpyral; Bayer Corporation, Spokane,
WA, USA) in one course of preseasonal treatment (SCIT
group) as recommended by the manufacturer (Fig. 1). On
average, patients received 13.8 injections (between 11 and 17)
and a mean cumulative dose of 5512.9 PNU was administered.
Seven patients with allergic rhinoconjunctivitis, two of them
with concomitant asthma, received only treatment with anti-
inﬂammatory drugs (non-SCIT group) during the pollinosis
season.
Blood samples were taken before treatment in January/
February 2000 (time point T0), after one course of SCIT in
May/June 2000 (T1), and 5 years later in July/August/
September 2005 (T2) (Fig. 1).
The clinical effects of immunotherapy and of anti-inﬂam-
matory treatment were evaluated on the basis of symptom
scores and the need for rescue medication. Symptoms were
determined according to a scale ranging from 0 to 3 points
(0 – no, 1 – mild, 2 – moderate, 3 – severe symptoms) for
the following symptoms: nasal obstruction, itching, sneez-
ing, rhinorrhea, and eye symptoms (as well as cough and
dyspnea). After SCIT, patients kept a diary for 2 weeks
during the pollen season (June 2000) where they reported
their daily symptoms and medication. For these patients,
the mean daily symptom score was calculated as follows:
the sum of the daily symptom scores per patient was calcu-
lated for the period of the 2-week monitoring and divided
by 14.
The scores for patients from the non-SCIT group at T1
were determined during consultations. Symptom scores at T0
as well as at T2 were collected for both groups during consul-
tations.
Patients from both groups were allowed to take the anti-
histamine loratadine, the nasal glucocorticoid beclometha-
sone, and the b2-adrenergic receptor agonist salbutamol as
rescue medications. The number of days with rescue medica-
Jan Feb Mar Apr
Year 1999 Year 2000 Year 2005
May Jun Jul
SCIT treatment
Jul Aug Sept
T0 T2T1Recruitment
Figure 1 Patients were recruited in summer 1999 to establish a
baseline symptom score. At time point T0 (January/February 2000),
patients from the subcutaneous injection immunotherapy group
received vaccination treatment. Vaccination was stopped after
5 months in the grass pollen season 2000, and patients were moni-
tored immediately thereafter (T1) and after 5 years (T2).
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tion during the 2-week assessment period in summer 2000
(T1) was noted by each patient and used to calculate the
total days and mean days medication/patient.
ELISA measurements of IgG1–4, IgA, and IgM
Sera were analyzed for IgG1–4, IgA, and IgM responses
against recombinant allergens from timothy grass pollen as
described (11). Each allergen (5 lg/ml in 0.1 M bicarbonate
buffer, pH 9.6) was coated to ELISA plates (Nunc, Roskilde,
Denmark) and was incubated with sera diluted as follows:
IgG1-4: 1 : 50, IgA and IgM: 1 : 100, or with buffer alone.
IgA and IgM detections were also performed at lower serum
dilutions (1 : 10, 1 : 25, 1 : 50). Bound antibodies were
detected with mouse monoclonal anti-human IgG1 (clone
JDC-1), IgG2 (clone G18-21), IgG4 (clone JDC-14), IgA1/2
(clone G18-1), and IgM (clone JDC-15) (PharMingen, San
Diego, CA, USA) or mouse monoclonal anti-human IgG3
(clone HP-6050) (Sigma-Aldrich, St Louis, MO, USA)
(12–15). All determinations were performed in duplicates,
and results are displayed as mean values with a mean coefﬁ-
cient of variation of 6.5%. Serum from a patient with deﬁned
antibody levels was added to each ELISA plate for calibra-
tion. Cutoffs were determined using the buffer control, which
yielded mean OD values of 0.025 for IgG, 0.023 for IgA, and
0.022 for IgM determinations.
Allergen-specific quantitative IgE measurements
Serum IgE reactivities against recombinant allergens and, for
control purposes, against human serum albumin were deter-
mined in a quantitative RAST-based, nondenaturing dot blot
assay under conditions of allergen excess (16). Allergens were
immobilized to nitrocellulose by dot blotting (0.2 lg/dot).
Bound IgE antibodies were detected with 125I-labeled anti-
human IgE (Phadia AB, Uppsala, Sweden) diluted 1 : 15 in
blocking buffer and were visualized by autoradiography and
quantiﬁed (counts per minute: cpm) using a gamma counter
(1277 Gammamaster; LKB, Wallac, Gaithersburg, MD,
USA) (16).
The percentages of increase or reduction in the median IgE
binding were determined according to the following formula:
% increase/reduction = 100 · median cpmT1/median cpmT0
) 100, where cpmT1 represent the cpm after incubation of the
dotted allergen with post-treatment sera and cpmT0 represent
the cpm after incubation with pretreatment sera.
ELISA measurement of allergen-specific light-chain binding
Patients’ sera were analyzed for light chain-speciﬁc binding
to puriﬁed recombinant allergens. ELISA plates (Nunc) were
coated with allergens (5 lg/ml) and were incubated with
1 : 50 diluted sera (or buffer).
Serum from a patient with deﬁned antibody levels was
added to each ELISA plate to allow a comparison of results
from different plates. Bound antibodies were detected with
mouse monoclonal anti-human kappa or anti-human lambda
light-chain antibodies (Sigma) and were traced with a
horseradish peroxidase-labeled sheep anti-mouse antiserum
(Amersham Biosciences) diluted 1 : 2000. Results are means
of duplicate determinations with a mean coefﬁcient of varia-
tion of 1.85%. Cutoff of the ELISA was determined using
the buffer control (mean OD value of 0.029).
Basophil degranulation experiments
T0, T1, and T2 sera from two SCIT group patients and from
two non-SCIT patients where sufﬁcient serum was available
were heat-inactivated for 4 h at 56C in order to remove IgE
reactivity (17). Then, sera were diluted 1 : 10 and pre-incu-
bated overnight with 0.01 lg/ml rPhl p 5 in Tyrode’s buffer
(18). In parallel, RBL cells expressing human FceRI (19)
(1 · 105/well) were loaded with serum IgE from non-heat-
inactivated T0 serum samples at a dilution of 1 : 10 over-
night. Cells were washed three times with Tyrode’s buffer
and exposed to the pre-incubated T0, T1, and T2 serum sam-
ples containing allergen immune complexes for 1 h. Superna-
tants were analyzed for b-hexosaminidase activity as
described (18). Results (single determinations owing to serum
shortness) are reported as percentages of total b-hexosamini-
dase released after addition of 10% Triton X-100.
Statistical analysis
Because of the skewed distribution of OD and cpm values,
data were log-transformed before analysis, resulting in distri-
butions of residuals not deviating signiﬁcantly from a normal
distribution in the Lilliefors corrected Kolmogorov–Smirnov
test. These data were subjected to ANOVA with repeated mea-
surements. Homogeneity of variances was tested by Levene’s
tests. Comparisons between time points were made by linear
contrasts against the baseline. No correction for multiple
testing was applied. P-values below 0.05 were considered
signiﬁcant.
Results
Subcutaneous injection immunotherapy patients develop
IgG1, IgG2, and IgG4 responses primarily against Phl p 1,
Phl p 2, Phl p 5, and Phl p 6 but no relevant allergen-specific
IgA or IgM antibody levels
As shown in Fig. 2, vaccinated patients signiﬁcantly increased
their IgG1 responses against each of the analyzed allergens
except against Phl p 12 after one course of SCIT. The
increases in IgG1 and IgG4 against Phl p 1, Phl p 2, Phl p 5,
and Phl p 6 were strong (Fig. 2A,C), whereas the increases in
allergen-speciﬁc IgG2 were more moderate but nevertheless
highly signiﬁcant (P < 0.001) (Fig. 2B). No relevant changes
in allergen-speciﬁc IgA (serum dilution 1 : 100; Fig. 2D) and
IgM (serum dilutions: 1 : 10, 1 : 25, 1 : 50) responses were
observed for the vaccinated group. Only a slight increase in
allergen-speciﬁc IgA was noted at a serum dilution of 1 : 10.
Five years after vaccination, the IgG antibody responses
were comparable to those found in the pretreatment serum
samples (Fig. 2A–D). Patients from the group receiving only
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anti-inﬂammatory treatment showed no relevant increases in
allergen-speciﬁc IgG, IgA, or IgM responses compared with
the vaccinated group (Fig. 2A–D).
Subcutaneous injection immunotherapy blunts the boost of
allergen-specific IgE responses
Figure 3 shows the development of allergen-speciﬁc IgE levels
for the major timothy grass pollen allergens Phl p 1 and Phl
p 5 and for the unrelated birch pollen allergen Bet v 1. By
comparing the median IgE levels in serum samples at T0 and
T1, we found a reduction in the median Phl p 1-speciﬁc IgE
levels in the range of 16.45% for the vaccinated group,
whereas the median Phl p 1-speciﬁc IgE levels increased
slightly in the group of patients receiving only anti-inﬂamma-
tory treatment. This effect was much stronger for the highly
immunogenic grass pollen allergen Phl p 5 (20). A median
decrease in Phl p 5-speciﬁc IgE levels in the range of 30%
was observed for the vaccinated group, whereas strong boost
of Phl p 5-speciﬁc IgE of 136% was noted for the patients
with only anti-inﬂammatory treatment. Concerning Bet v 1,
the comparison of allergen-speciﬁc IgE levels at T0 and T1
showed a similar increase in median IgE levels in the vacci-
nated group and in patients with anti-inﬂammatory treatment
only (i.e., SCIT group: +122%; non-SCIT group: +139%).
Phl p 5-speciﬁc IgE levels in T2 were higher in both groups
compared with those in T0, whereas Phl p 1-speciﬁc IgE
levels in T2 were comparable with those in T0 in both groups
as observed for the unrelated birch pollen allergen Bet v 1
(Fig. 3).
Therapy-induced antibodies utilize both kappa and lambda
light chains
In order to investigate the contribution of kappa and
lambda chains in the vaccine-induced IgG responses, we
determined allergen-speciﬁc kappa and lambda reactivities in
the sera. Figure 4 shows that only vaccinated patients exhi-
bit a signiﬁcant induction of kappa and lambda responses
against the major allergens Phl p 1 and Phl p 5 from T0 to
T1. This response decreased after 5 years. For the minor
allergens, Phl p 7 and Phl p 12, no signiﬁcant development
of light chain responses could be detected. The time
courses/kinetics and levels of allergen-speciﬁc IgG1 and
IgG4 responses shown in Fig. 2A,C are similar to those of
the light-chain responses but not to those of the other anti-
body classes and subclasses, suggesting that the detected
light chains belong to the corresponding IgG1 and IgG4
heavy chains.
Reduction in allergen-induced basophil degranulation in
SCIT-treated patients
We found that serum samples obtained after SCIT which
had increased allergen-speciﬁc IgG inhibited basophil
degranulation strongly (Fig. 5). At T1, serum from patient 4
caused an 89% inhibition of basophil degranulation and
serum from patient 5 a 42% inhibition compared with that
at T0. Serum from patient 4 showed reduced blocking activ-
ity after 5 years, which was associated with lower allergen-
speciﬁc IgG levels at T2 in this serum (IgG1: T0: 0.547, T1:
1.673, T2: 0.226; IgG4: T0: 0.244, T1: 1.646, T2: 0.107;
Fig. 5). Serum from patient 5 obtained at T2 showed even
stronger inhibition of basophil degranulation than serum
obtained at T1. This effect was associated with maintained
allergen-speciﬁc IgG levels in this serum (IgG1: T0: 0.463,
T1: 1.981, T2: 1.096; IgG4: T0: 0.116, T1: 0.414, T2: 0.353;
Fig. 5).
Sera obtained from patients who had received only
anti-inﬂammatory medication did not show any relevant
inhibition of allergen-induced basophil degranulation at T1
or T2 compared with that at T0 (Fig. 5, right).
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Figure 3 Box plot representation of IgE levels (cpm: y-axes) to rPhl
p 1, rPhl p 5, and rBet v 1 is shown for the subcutaneous injection
immunotherapy (SCIT) group and non-SCIT group patients before
the trial (T0), 5 months after T0 (T1), and 5 years later (T2). Altera-
tions of the median allergen-specific IgE levels between T0 and T1
are expressed as percentage increases (+) or decreases ()). Boxes
include 50% of the values, and nonoutliers are located between the
bars. Circles and asterisks indicate outliers and extremes, respec-
tively. Lines within the boxes denote median values. P-values of
<0.05 are displayed.
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Development of symptoms following SCIT treatment and
after 5 years
In the SCIT group, median symptom scores declined signiﬁ-
cantly (P < 0.001) from 8.5 points to 2.1 points after
5 months of SCIT (Fig. 6). Five years later, this effect showed
only moderate signiﬁcance (P < 0.05) and the reported med-
ian scores went back to 6.5 points. The median score at time
point T0 in the non-SCIT group was 9 and thus was very sim-
ilar to the 8.5 points in the SCIT group before treatment.
Patients receiving only anti-inﬂammatory treatment showed
almost no clinical improvement with a symptom score of 8
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Figure 4 Box plot representation of kappa and lambda light chain
levels (OD values: y-axes) to recombinant timothy grass pollen aller-
gens (rPhl p 1, rPhl p 5, rPhl p 7, rPhl p 12) is shown for the subcu-
taneous injection immunotherapy (SCIT) group and non-SCIT group
patients. Reactions are displayed before the trial (T0), 5 months
after T0 (T1), and 5 years later (T2). Boxes include 50% of the val-
ues, and nonoutliers are located between the bars. Circles and
asterisks indicate outliers and extremes, respectively. Lines within
the boxes denote median values. P-values of <0.05 or <0.001
respectively are displayed.
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Figure 5 Influence of allergen-specific IgG in patients sera on
rPhl p 5-induced basophil degranulation. RBL cells were loaded with
pretreatment serum IgE from two treated (left: 4, 5) and two non-
treated (right: C13, C14) patients. Cells that had been loaded with
IgE from a patient were then exposed to IgE-depleted sera from
the very same patient obtained before the trial (T0), 5 months after
T0 (T1), or 5 years thereafter (T2). ß-Hexosaminidase releases are
displayed as percentages of total releases. Alterations of the
releases are indicated as percentage increase or decrease com-
pared with those of the earlier time point.
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points in summer 2000 and of 7 points in summer 2005,
5 years after treatment. Five years after discontinuation of the
study, patients from the SCIT group showed a lower symp-
tom score than the patients from the non-SCIT group, which
was of moderate signiﬁcance (P < 0.05). The number of
patients with asthma did not increase in the two groups at T2.
Table 1 shows the number of days during which patients
had consumed rescue medication and the mean number of
days/patient with rescue medication at time point T1.
Patients in the non-SCIT group took more often loratadine
(75 days; mean 10.7 days/patient) than patients from the
SCIT group (58 days; mean 4.8 days/patient). This was partly
outweighed by a higher consumption of nasal beclometha-
sone in the SCIT group (38 days; mean 3.2 days/patient)
compared with the non-SCIT group (0 days). When the total
medication including salbutamol was calculated, we found
that the SCIT group had even consumed less often rescue
medication (101 days; mean 8.4 days/patient) than the non-
SCIT group (77 days; mean 11 days/patient). These observa-
tions indicate that clinical improvement was not caused by
higher consumption of rescue medication.
Discussion
Here, we performed an observational pilot study in which we
used a panel of recombinant timothy grass pollen allergens to
study allergen-speciﬁc antibody levels in grass pollen–allergic
patients who had received one course of injection immuno-
therapy and in patients who had received anti-inﬂammatory
treatment. We found a strong induction of speciﬁc
IgG1 > IgG4 > IgG2 but no relevant induction of IgM or
IgG3 levels speciﬁc for allergens included in the vaccine (11,
21–26). As described by other authors (27), a slight increase in
allergen-speciﬁc IgA was noted, but given the fact that it was
obvious at a very low serum dilution of 1 : 10, the clinical rel-
evance of this increase is uncertain. IgG antibodies were not
induced against all grass pollen allergens, and the levels of
allergen-speciﬁc IgG varied between the individual allergens.
Increases in IgG responses against allergens (e.g., Phl p 7, Phl
p 12, Phl p 13) which may be absent from allergen extracts or
exhibit poor immunogenicity were low or not detectable (28).
The testing for the usage of kappa and lambda light chains
provided a hitherto unknown result, i.e., that SCIT induces
allergen-speciﬁc reactivity of both kappa and lambda light
chains. We think that the increase in light-chain reactivity is
primarily attributable to the occurrence of lambda and kappa
light chains in the allergen-speciﬁc IgG fraction because there
was a parallel increase in similar magnitudes in IgG and light
chain binding. Furthermore, free light chains reportedly have
anaphylactic but not protective activity as shown in our baso-
phil experiment (29). This ﬁnding indicates that SCIT induces
a de novo immune response via a balanced activation of kappa
and lambda bearing B cells.
In the majority of SCIT-treated patients, allergen-speciﬁc
IgG responses declined to pretreatment levels 5 years after
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Figure 6 Box plot representation of the development of symptoms
in the subcutaneous injection immunotherapy (SCIT) and non-SCIT
group. Symptom scores (y-axis) are shown for each group before
treatment in summer 1999, at time point T1 in summer 2000, and
5 years later in summer 2005 (T2). Boxes include 50% of the val-
ues, and nonoutliers are located between the bars. Circles and
asterisks indicate outliers and extremes, respectively. Lines within
the boxes denote median values. Significant differences (P-values
of <0.05 or <0.001) are displayed.
Table 1 Days with rescue medication (loratadine, salbutamol, beclomethasone) are reported for subcutaneous injection immunotherapy
(SCIT) group (n = 12) and non-SCIT group patients (n = 7). For each single drug as well as for total medication, the total days of usage are
shown and further the mean days per patient are indicated
Days with loratadine Days with salbutamol
Days with
beclomethasone Total
Total
days
Mean
days/patient
Total
days
Mean
days/patient
Total
days
Mean
days/patient
Total
days
Mean
days/patient
SCIT group n = 12 58 4.8 5 0.42 38 3.2 101 8.4
Non-SCIT group n = 7 75 10.7 2 0.3 0 0 77 11
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treatment. In a study performed with hypoallergenic deriva-
tives of the major birch pollen allergen, Bet v 1, it was also
found that therapy-induced IgG decreased already 1 year
after treatment and that at this time point patients had
regained sensitivity when subjected to nasal allergen provoca-
tion (24, 30). Using a recently established basophil degranula-
tion assay that allows determining the effects of blocking
antibodies on basophil sensitivity for serum samples obtained
before and after treatment, we show that the reduction in
basophil degranulation depends on the presence of allergen-
speciﬁc IgG antibodies, because no relevant alterations of
allergen-speciﬁc antibody levels were noted for other immu-
noglobulin classes. Pauli et al. recently showed in a double-
blind placebo-controlled SCIT trial performed with puriﬁed
recombinant Bet v 1, natural Bet v 1, and birch pollen
extract that clinical improvement and reduction in skin/mast
cell sensitivity are associated with the induction of allergen-
speciﬁc IgG (26).
Three studies demonstrated that patients who have devel-
oped allergen-speciﬁc IgG during SCIT exhibit reduced
boosts of allergen-speciﬁc IgE (23, 24, 31) or a decrease in
allergen-speciﬁc IgE when treatment was performed for sev-
eral years (2, 3). One possible explanation for the decrease in
allergen-speciﬁc IgE is that patients develop allergen-speciﬁc
IgG which prevent boosts of allergen-induced IgE production
(32–34).
If elevated allergen-speciﬁc IgG can be maintained for a
long period by SCIT, allergen-speciﬁc IgE levels may decline
as under lack of allergen exposure. This may lead to reduced
loading of mast cells with IgE antibodies and reduced clinical
sensitivity. The latter mechanisms may play a role for the
long-lasting effects of SCIT, which have been reported to be
associated with reductions of allergen-speciﬁc IgE levels and
skin sensitivity (2, 3). Also, the decrease in Th2 cell activation
observed for grass pollen immunotherapy (4) may be associ-
ated with the effects of blocking antibodies that block IgE-
facilitated allergen presentation to T cells (35–39).
Although it is known that SCIT and SLIT can induce rises
in allergen-speciﬁc IgE, we found a trend toward a reduction
in allergen-speciﬁc IgE levels after one course of SCIT but
not in the patients receiving anti-inﬂammatory treatment.
This effect may be explained by the suppression of boosts of
IgE production owing to grass pollen exposure by SCIT-
induced IgG as reported earlier (23, 24, 31). However, the
reduction in IgE levels was only detected shortly after treat-
ment but not after 5 years, which may explain why only a
moderate long-term clinical effect was achieved in this study.
In summary, our results may indicate that more than one
course of preseasonal SCIT is necessary to maintain high
levels of allergen-speciﬁc IgG for a period long enough to
achieve a sustainable reduction in allergen-speciﬁc IgE levels
leading to long-lasting and relevant clinical effects.
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Abstract 
Background: Affinity and clonality of allergen-specific IgE antibodies are important 
determinants for the magnitude of IgE-mediated allergic inflammation.  
Objective: To analyze the contribution of heavy and light chains of human allergen-
specific IgE antibodies for allergen-specificity and to test if promiscuous pairing of 
heavy and light chains with different allergen specificity allows binding and may affect 
affinity.   
Methods: Ten IgE Fabs specific for three non-cross-reactive major timothy grass 
pollen allergens (Phl p 1, Phl p 2, Phl p 5) obtained by combinatorial cloning from a 
grass pollen allergic patient were used to construct stable recombinant ScFvs 
representing the original Fabs as well as shuffled ScFvs in which heavy chains were 
recombined with light chains from IgE Fabs with specificity for other allergens using 
the pCANTAB 5 E expression system. Possible ancestor genes for the heavy chain 
and light chain variable region-encoding genes were determined by sequence 
comparison with the IMGT data base and their chromosomal locations were 
determined. Recombinant ScFvs were tested for allergen-specificity and affinity by 
ELISA and surface plasmon resonance experiments, respectively.   
Results: The shuffling experiments demonstrate that promiscuous pairing of heavy 
and light chains is possible and maintains allergen-specificity which is mainly 
determined by the heavy chains. ScFvs consisting of different heavy and light chains 
exhibited different affinities for the corresponding allergen.   
Conclusion: Our results indicate that allergen-specificity of allergen-specific IgE is 
mainly determined by the heavy chains. Different heavy and light chain pairings in 
allergen-specific IgE antibodies affect affinity and thus may influence clinical 
reactivity to allergens.  
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Key message: Allergen-specificity in IgE-derived grass pollen allergen-specific ScFvs 
were dictated by the heavy chains. Different pairings of heavy and light chains 
resulted in differences in affinity of allergen recognition and thus may affect clinical 
sensitivity.      
 
Capsule summary: Heavy chains seem to determine allergen-specificity in allergen-
specific IgE antibodies. Promiscuous pairing of heavy and light chains may contribute 
to polyclonality as well as to diversity, modulate affinity and thus clinical sensitivity.   
 
Key words: Allergy, allergen, IgE antibodies, specificity, affinity. 
 
Abbreviations used: 
VH: heavy chain variable region 
VL: light chain variable region 
ScFv: single-chain variable fragment 
aa: amino acid 
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Introduction 
Immunoglobulin E (IgE) is the key immunoglobulin mediating allergic inflammation . 
When allergens cross-link mast cell- or basophil-bound IgE, the release of 
inflammatory mediators, cytokines and proteases is induced . Furthermore, IgE 
facilitates the presentation of allergens to T cells and thus may contribute to T cell-
mediated chronic inflammation .  
1
2
3
Both the levels of IgE antibodies in allergic patients as well as the amounts of 
allergen to which allergic patients are usually exposed are extremely low . 
Nevertheless, small amounts of IgE-allergen immune complexes are able to induce 
strong inflammatory reactions which may be explained by the high affinity of IgE to 
FcRI on mast cells and basophils and also by high affinity recognition of allergens 
by IgE . In fact, the 
1
1, 4, 5 three dimensional structures of two IgE-allergen complexes 
have recently been solved by X-ray crystallography and revealed high affinity binding 
of allergen-specific human IgE to conformational epitopes on the corresponding 
allergens .  4, 5
Several studies suggest that the mode of interaction between IgE and allergens has 
profound effects on clinical symptoms in allergic patients. It has been shown that the 
magnitude of basophil degranulation increases with the number of IgE epitopes on a 
given allergen and thus with the clonality of the IgE response as well as with the 
levels of allergen-specific IgE and with the affinities of IgE antibodies for the allergen 
. Despite the importance of the IgE allergen interaction in allergy, only limited 
information regarding the structure of allergen-specific human IgE antibodies and 
their mode of interaction with the allergens is available. 
6, 7
The analysis of the primary structure of allergen-specific IgE from allergic patients 
has mainly become possible through combinatorial cloning because so far no 
technology is available to establish a representative repertoire of IgE producing cell 
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lines from allergic patients . The analysis of allergic patients’ allergen-specific 
IgE Fabs or ScFvs shows that these molecules bind with high specificity and affinity 
to the corresponding allergens, show a varying degree of somatic mutations and 
there seems to be quite a broad usage of the individual VH regions . Analyzing 
allergen-specific IgE Fabs it has been noted that certain IgE heavy chains can 
recombine with different light chains and retain the specificity for the allergen . 
On the other hand human IgE-derived allergen-specific Fabs or ScFvs have been 
described in which different heavy chains combined with the same light chain . In 
this study we analyzed the contribution of heavy chains and light chains for 
determining the specificity of allergen-recognition by recombining IgE heavy chains 
from grass pollen allergen IgE Fabs with different light chains. For this purpose we 
engineered stable ScFvs representing the original IgE Fabs isolated from allergic 
patients and shuffled versions in which light chains with specificities for other 
allergens were inserted. The recombinant ScFvs were then tested for allergen-
specificity and affinity by ELISA and surface plasmon resonance measurements.  
4, 5, 7-16
4, 5, 7-17
9, 10, 16
7, 8
 
 
 
 72
MANUSCRIPT 2 
Material and Methods 
 
Recombinant allergens 
Recombinant grass pollen allergens rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6 and rPhl p 7 
(timothy grass) and recombinant major birch pollen allergen, rBet v 1, were 
purchased from Biomay (Vienna, Austria), rPhl p 12 and rPhl p 13 (timothy grass) 
were expressed and purified as described 18, 19.  
 
Characterization of grass pollen allergen-specific IgE Fabs 
IgE Fabs specific for major timothy grass pollen allergens Phl p 1, Phl p 2 and Phl p 5 
were isolated from a combinatorial pComb 3H-phagemid library constructed from 
PBMCs of a grass pollen allergic patient 16. In total, four IgE Fab clones specific for 
Phl p 5 (clones 5, 14, 28, 31), three specific for Phl p 2 (clones 94, 60, 100) and three 
specific for Phl p 1 (clones 25, 43, 10) were used as starting material for the 
engineering of defined ScFvs 11, 14, 16.  
DNA sequences coding for the heavy and light chain variable regions were aligned 
with human germ line gene sequences (allele*01) from the ImMunoGeneTics (IMGT) 
database using V-Quest software 20. For each of the analyzed heavy and light chain 
sequences the corresponding germ line V, D and J genes with the highest sequence 
identities and those with sequence identities with no less than 5% to the latter 
(highlighted in bold) (Table E1) were mapped on chromosome locus 14q32.33 
(heavy chains) 21 or on chromosome locus 2p11.2 (light chains) 22 (Fig 1). The light 
chain DNA sequences were translated (ExPASy, Swiss Institute of Bioinformatics, 
Geneva, Switzerland) and the deduced amino acid sequences were aligned (Fig 2) in 
order to compare the individual chains. Sequence identities were calculated using the 
multiple sequence alignment program clustal W 23 (Table E2).  
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Conversion of allergen-specific IgE Fabs into ScFvs and light chain-shuffled 
ScFvs  
Using the pComb 3H phagemid DNA from clones 5 (Phl p 5), clone 94 (Phl p 2) and 
clone 25 (Phl p 1) as template the heavy chain cDNAs were amplified by PCR using 
20pmol of an equimolar mix of IgHV- and IgHJ-family specific ScFv primers 24. In 
parallel, cDNAs coding for 10 light chains of the original IgE Fabs (Phl p 5: clones 5, 
14, 28, 31; Phl p 2: clones 94, 60, 100; Phl p 1: clones 25, 43, 10) were PCR 
amplified using IgKV and IgKJ-family specific primers 24. PCR products were purified 
on a 1% agarose gel. 
Fifty ng of DNA coding for VH and VL fragments were assembled to obtain ScFv 
cDNAs. The combination of heavy and light chain fragment-encoding cDNAs of the 
original Fab clones (clones 5, 94, 25) resulted in corresponding ScFv cDNAs giving 
rise to ScFvs specific for Phl p 5 (5VH/5VL), Phl p 2 (94VH/94VL) and Phl p 1 
(25VH/25VL). In parallel, cDNAs coding for the VH fragments were recombined with 
light chains from IgE Fabs with other specificities to obtain shuffled ScFvs which 
were designated according to the clones from where the heavy chain and light chain 
cDNAs were obtained (heavy chain/light chain: 5VH/94VL, 5VH/60VL, 5VH/100VL, 
5VH/25VL, 5VH/43VL, 5VH/10VL, 94VH/5VL, 94VH/31VL, 94VH/14VL, 94VH/28VL, 
94VH/25VL, 94VH/43VL, 94VH/10VL, 25VH/5VL, 25VH/31VL, 25VH/14VL, 
25VH/28VL, 25VH/94VL, 25VH/60VL, 25VH/100VL).  
The PCR assembly was performed by introducing a linker DNA coding for a 15 
amino acids linker (Gly4Ser)3 24. The production of the human linker DNA is 
described in the online repository material. Assembly PCR was run for seven cycles 
(Mouse ScFv module/Amersham Biosciences, Little Chalfont, UK) and the 
assembled sequence was further amplified by adding an equimolar mix of 20 pmol 
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IGHV and IGKJ outer primers containing restriction sites for SfiI (IGHV) and NotI 
(IGKJ) 24. Products were purified on a 1% agarose gel and eluted as described.  
Purified ScFv cDNA was digested with SfiI and NotI (New England Biolabs, Ipswich, 
MA, USA), purified on a 1% agarose gel and further ligated into the phagemid vector 
pCANTAB 5 E (Amersham Biosciences). Recombinant phagemid DNA was 
transformed into the E. coli strain HB2151 by electroporation for the production of 
soluble ScFv fragments (Expression module/Recombinant phage antibody system, 
Amersham Biosciences). E. coli cells were grown on SOBAG plates (Expression 
module, Amersham Biosciences) at 30°C over night.  
ScFv expressing clones were identified by sequencing (Eurofins MWG Operon, 
Ebersberg, Germany) using the ScFv-specific primers pCANTAB 5 E_fwd (5’ CCA 
TGA TTA CGC CAA GCT TTG GAG CC 3’) and pCANTAB 5 E_rev (5’ GTA AAT 
GAA TTT TCT GTA TGA GG 3’) and by testing supernatants for reactivity to the 
allergens. For this purpose, transformed bacteria were induced with 1 mM IPTG to 
express soluble ScFv and tested for allergen specificity by ELISA.  
ScFvs were further tested for reactivity with an antibody directed to the C-terminal 
peptide tag (E tag) by immunoblotting (Schleicher & Schuell, Dassel, Germany) 25. 
Membrane-bound ScFvs were traced with a monoclonal mouse anti-E tag antibody 
(Amersham Biosciences) followed by a horseradish peroxidase-labelled sheep anti-
mouse antiserum (Amersham Biosciences). Blots were developed with the ECL Plus 
Western Blotting Detection System (GE Healthcare) followed by exposure to Kodak 
XOMAT films with intensifying screens (Kodak, Heidelberg, Germany).  
 
Determination of binding specificities by ELISA  
Bacterial lysates containing soluble ScFvs were analyzed for specific binding to 
recombinant timothy grass pollen allergens (Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, 
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Phl p 12, Phl p 13), to the major birch pollen allergen Bet v 1 and to HSA as controls. 
Five µg/ml of the proteins in PBS were coated to ELISA plates (Nunc, Roskilde, 
Denmark) and incubated with the ScFv-containing lysates diluted 1:2 in blocking 
buffer (PBS/3% w/v BSA) or, for control purposes, with blocking buffer alone. For 
calibration, lysates from the 5VH/5VL clone were added to each plate. Bound ScFv 
fragments were detected with the monoclonal mouse anti-E tag antibody (Amersham 
Biosciences) and traced with a horseradish peroxidase-labelled sheep anti-mouse 
antiserum (Amersham Biosciences). The colour reaction was read at 405 nm 26. All 
samples were analyzed in duplicates, the means were calculated and after 
subtraction of the baseline signal (i.e., signal obtained with the unrelated allergen Bet 
v 1) were displayed as mean OD values.  
 
Determination of kinetics and binding affinities of ScFvs  
All measurements were performed on a BIACORE 2000 instrument at 25°C. In order 
to activate the surface of a CM5 sensor chip flow cell (BIACore AB), a 1:1 mixture of 
1-ethyl-3-(3-dimethylaminopropyl carbodiimide) hydrochloride (EDC) and N-
hydroxysuccinimide (NHS) was injected at a flow rate of 5 µl/min for 7 minutes. To 
serve as capturing antibody, 60 µg/ml of the monoclonal anti-E tag antibody 
(Amersham Biosystems) diluted in 10 mM sodium acetate (pH 5) were injected at a 
flow rate of 10 µl/min until the maximal immobilization level of approximately 10 000 
resonance units (RU) was reached. The flow cell was then deactivated by injection of 
1 M ethanolamine-HCl (pH 8.5) (5 µl/min) for 7 minutes. The reference cell was 
loaded with an isotype control antibody in an analogous way. Lysates containing 
ScFvs diluted in HBS-EP (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005 % v/v 
surfactant P20, pH 7.4) were injected at 5 µl/min for different periods of time followed 
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by a stabilization phase of 30 minutes in order to capture 100 RU of ScFv for a 
calculated Rmax of 100 RU.  
For the determination of kinetics and binding affinities, multi cycle kinetic was 
performed. For this purpose, the tested allergen was diluted in HBS-EP in 2-fold 
increasing concentrations (0.125 – 128 nM) and injected in random order at 30 µl/min 
for 5 minutes. Dissociation was determined by injection of HBS-EP buffer at 30 µl/min 
for 30 minutes. For control purposes, two runs were performed with the same 
allergen dilutions. In addition, two cycles were run with HBS-EP alone in order to 
subtract background signals. Regeneration of the sensor chip was performed by 
injection of 10 mM glycine-HCl, pH 2.5 at 30 µl/min for 30 seconds. BIAEvaluation 
3.2 (BIACore AB) software was used to calculate kinetics and affinity constants, 
fittings were performed with a 1:1 (Langmuir) binding model.  
For ScFvs showing weak binding in the ELISA (i.e., 25VH/14VL, 25VH/28VL) Biacore 
experiments were performed in order to verify binding reactions. After capturing of 
100 RU of ScFv, 256 nM of the respective allergens were injected at a flow rate of 30 
µl/min for 5 minutes. For double referencing, running buffer (HBS-EP) was injected 
under the same conditions.  
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Results 
Sequence analysis of human IgE Fabs specific for three non-cross-reactive 
grass pollen allergens.  
VH and kappa VL cDNAs from the ten IgE Fabs specific for three non-cross-reactive 
allergens obtained from the combinatorial library were compared with human germ 
line genes from the IMGT database.  
Sequence analysis and comparison with the germ line genes revealed that the four 
Phl p 5-specific IgE Fabs used the very same heavy chain (5VH) which had 
recombined with four different light chains (5VL, 14VL, 28VL, 31VL) (Table E1A). The 
heavy chains of the three Phl p 2-specific IgE Fabs (94VH, 60VH, 100VH) seemed to 
utilize the same IGHV genes (Table E1A). Interestingly, two (94VH, 60VH) seemed 
to have recombined with similar light chains (94VL, 60VL) which were also used by 
Phl p 5-specific IgE Fabs (14, 28, 31) and one (100VH) used a light chain identical to 
that of one of the four Phl p 5-specific IgE Fab (5VL) (Tables E1A, B, E2). All three 
Phl p 1-specific IgE Fabs were derived from the same IGHV gene and also contained 
light chains based on IGKV genes which appeared similar to those used by three of 
the Phl p 5-specific IgE Fabs (i.e., 14, 28, 31) (Tables E1A, B). However, the 
alignment of the light chains in Figure 2 showed that their similarity was mainly due to 
the usage of the same V genes (Table E1B), whereas most of them showed high 
diversity in the amino acid composition within CDR1 and CDR3 (Fig 2).  
Possible ancestor genes for Phl p 5-, Phl p 2- and Phl p 1-specific IgE VHs are 
distributed along the heavy chain locus on chromosome 14 (14q32.33) (Fig 1A), and 
arise from different VH genes belonging to the IGHV3 and IGHV4 family (Fig 1A, 
Table E1A). In Table E1 the closest related IGHV germ line gene and those germ line 
genes with a difference in sequence of less than 5% are coloured. Within this range, 
4 and 2 of the 23 functional IGHV3 genes may be considered as possible ancestors 
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for Phl p 5-specific (IGHV3-30-3, IGHV3-30, IGHV3-33, IGHV3-NL1) and Phl p 1-
specific (IGHV3-9, IGHV3-20) variable regions, respectively. Considering the same 
range of sequence identity at least 5 of the 11 functional genes may be considered 
as possible progenitors (IGHV4-31, IGHV4-30-4, IGHV4-30-2, IGHV4-61, IGHV4-59) 
for the Phl p 2-specific VH genes. 
The sequence comparison for the CDR3 regions with the possible corresponding 
IGHD and IGHJ genes was not possible due to their junctional diversity. Two of the 
Phl p 1 IgE Fabs (i.e., 43, 10) used similar IGHD genes whereas the third and the Phl 
p 2-specific IgE Fabs seemed to use different IGHD genes. The IGHJ genes in the 
IgE Fabs were similar (mainly IGHJ4*01) whereas the light chains used different 
IGKJ genes and thus may result from different somatic recombinations (Table E1A, 
B).   
Interestingly, the light chains of the IgE Fabs specific for different unrelated allergens 
(i.e., Phl p 5, Phl p 2, Phl p 1) seemed to evolve from one germ line gene pool (Table 
E1B) located on the kappa light chain locus on chromosome 2 (2p11.2) (Fig 1B). The 
possible germ line genes of the light chains all belonged to the IGKV1 family (IGKV1-
12, IGKV1D-12, IGKV1-39, IGKV1D-39, IGKV1D-16, IGKV1-17, IGKV1-9) (Fig 1B, 
Table E1B) involving 7 of 20 functional genes.  
 
Conversion of allergen-specific IgE Fab fragments into ScFv fragments with 
identical binding specificity and shuffling of heavy and light chains 
Expression of recombinant Fab fragments using the pComb 3H system may yield 
Fab preparations which consist of difficult to define mixtures of correctly formed Fabs 
and also incorrectly formed homo-dimers consisting of only heavy or light chains. In 
order to obtain high yields of defined and stable combinations of heavy and light 
chain fragments for binding experiments 27, recombinant IgE Fabs were converted 
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into ScFvs. Based on the sequences of the original IgE Fab fragments, stable ScFv 
fragments were generated in a first step (Fig 3). ScFvs containing the original 
combinations of heavy and light chains were termed “original” whereas those in 
which heavy chains were newly combined with light chains taken from Fabs with 
other specificities were designated “light chain-shuffled”.  
Table 1 gives an overview of the three original ScFvs (5VH/5VL, 94VH/94VL, 
25VH/25VL) and 18 light chain-shuffled ScFvs. The recombinant ScFvs contain an E 
tag at their C-terminus and therefore could be detected in E. coli lysates by 
immunoblotting as exemplified for certain clones in Fig 4. Light chain-shuffled ScFvs 
were obtained for all combinations except for 94VH/28VL which carried a frame shift 
mutation and for 25VH/31VL which contained a substitution mutation and thus 
resulted in a premature stop of translation (Fig 4; data not shown).  
 
Light chain shuffling in ScFvs indicates that allergen-specificity is mainly 
determined by the heavy chain 
The majority of the shuffled clones (12 out of 18) reacted with the allergen that was 
recognized by the original ScFv when tested by ELISA (Table 1).  
The Phl p 5-specific 5VH was successfully recombined with each of the six light 
chains and each of the light chain-shuffled ScFvs bound to Phl p 5 but not to other 
timothy grass pollen allergens (i.e., Phl p 1, Phl p 2, Phl p 6, Phl p 7, Phl p 12 and Phl 
p 13) (Fig 5A, Table 1).  
Likewise, the Phl p 2-specific 94VH and Phl p 1-specific 25VH recombined with the 
light chains and many of the light-chain-shuffled ScFvs bound to the VH-specific 
allergen but not to the other tested grass pollen allergens (Fig 5B, 5C, Table 1).  
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Surface plasmon resonance measurements confirm that light chain-shuffled 
ScFvs preserve the specificity of the original ScFvs and exhibit affinities in the 
nanomolar range  
Kinetics (i.e., association and dissociation rate constants) and binding affinities for 
the interaction between original and light chain-shuffled ScFvs and their respective 
allergens were measured using surface plasmon resonance. For this purpose, ScFvs 
were immobilized to the Biacore chip using the anti-E tag antibody for capturing and 
2-fold increasing concentrations of allergen were injected into the flow cell allowing 
interaction with the captured ScFv. Six ScFvs (two original and 4 light-chain-shuffled 
ScFvs) with positive ELISA results could be analyzed in Biacore experiments 
because they could be successfully captured with the anti-E tag antibody (Table 2).  
Among the ScFvs carrying the Phl p 5-specific 5VH the original ScFv 5VH/5VL 
showed the highest affinity to Phl p 5 (KD = 3.74 x 10-11 M) (Fig 6A, Table 2). The 
light chain-shuffled ScFv 5VH/25VL (Fig 6B) still bound with high affinity to Phl p 5 
(KD = 2.6 x 10-9 M) but the affinity was approximately 100-fold reduced compared to 
the original ScFv (Table 2). Likewise, the other two light chain-shuffled ScFvs 
(5VH/100VL, 5VH/43VL) showed lower affinities to Phl p 5 than the original ScFv 
(Table 2).  
The original Phl p 1-specific ScFv 25VH/25VL showed an affinity which was 
comparable to that of the Phl p 5-specific shuffled ScFv (5VH/100VL) (Table 2). The 
shuffled Phl p 2-specific ScFv 94VH/5VL showed a lower affinity which was 
comparable to two of the Phl p 5-specific shuffled ScFvs (5VH/25VL, 5VH/43VL).  
In this context we noted that certain amino acids which were involved in the binding 
of the light chain of the Phl p 2-specific IgE Fab to Phl p 2 4 were different in the 
shuffled version but binding was retained (Fig 2, printed in red). From the two 
contacts in the CDR1 of the light chain, one was conserved in all three ScFvs which 
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retained binding specificity (94VH/94VL, 94VH/5VL, 94VH/25VL). In CDR2, only one 
residue made contact which was conserved in each of the three binding ScFvs. 
Several contacts were observed for CDR3, but none of these amino acids was 
conserved in all three binding ScFvs. Despite the shuffling, each of the tested ScFvs 
showed binding affinities in the nanomolar range (Table 2).  
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Discussion 
In this study the contribution of heavy and light chains to the binding specificity and 
affinity of ScFvs derived from human IgE antibodies specific to allergens was 
investigated. Using heavy and light chains from human IgE Fabs 11, 14, 16 with 
specificity for three different immunologically unrelated major grass pollen allergens, 
Phl p 1 , Phl p 2 and Phl p 5 28-30 as a starting material we constructed and 
characterized stable recombinant ScFvs. Thus a defined experimental model system 
was obtained for testing the effects of variations in heavy and light chain pairing on 
allergen-specificity and affinity.  
When the various ScFvs were tested for reactivity to seven different grass pollen 
allergens we found that the original ScFvs bound with high specificity only to the 
allergens which were recognized by the corresponding original IgE Fabs. 
Interestingly, several of the shuffled ScFvs in which the original light chain was 
replaced by a light chain derived from an IgE Fab with specificity for another 
unrelated allergen retained their specificity to the original allergen in a heavy chain-
dependent manner. These results indicate that the heavy chain is important for 
determining the specificity in human allergen-specific IgE antibodies. According to 
the sequence comparison of the cDNAs coding for the IgE VHs with the germ line 
genes it seemed that the analyzed heavy chains are derived from several distinct 
ancestor genes. Therefore, allergen specificity may originate from several different 
genes which indicates a certain redundancy in allergen recognition by IgE antibodies 
and may contribute to diversity.  
Shuffled ScFvs containing different heavy and light chains showed different affinities 
to the corresponding allergens as measured by surface plasmon resonance 
experiments. This finding suggests that besides junctional diversity and varying 
affinity maturation by somatic mutations 31, pairing of different heavy and light chains 
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may contribute to the modulation of affinity in the allergen recognition by allergen-
specific IgE antibodies. We have not done epitope mapping of the binding sites of the 
original and shuffled ScFvs but it is possible that the shuffled versions may recognize 
different epitopes which may increase clonality. Variations of affinity and clonality 
through promiscuous heavy and light chain pairing may be of clinical importance 
because it has been shown that both, affinity and clonality of IgE recognition of 
allergens determines the intensity of effector cell degranulation 6, 7 and therefore 
could have an effect on the magnitude of immediate allergic inflammation. 
Promiscuous heavy and light chain pairing may thus represent a novel mechanism 
responsible for varying clinical sensitivities in allergic patients.  
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Table 1 
Characterization of ScFvs regarding expression and binding specificities
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Table 2 
 
Summary of Biacore results for ScFvs with allergen-specifity 
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ka (1/Ms) 2.23 x 105 n.a. n.a. 1.84 x 105 n.a. 9.91 x 104 1.31 x 105 9.94 x 104 n.a. n.a. n.a. n.a. 2.23 x 105
kd (1/s) 8.34 x 10-6 n.a. n.a. 6.46 x 10-5 n.a. 2.57 x 10-4 5.23 x 10-4 6.66 x 10-4 n.a. n.a. n.a. n.a. 1.23 x 10-4
KD (M) 3.74 x 10-11 n.a. n.a. 3.5 x 10-10 n.a. 2.6 x 10-9 4.01 x 10-9 6.71 x 10-9 n.a. n.a. n.a. n.a. 5.5 x 10-10
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Figure legends 
 
FIG. 1. Localization of the possible functional ancestor genes of the allergen-specific 
ScFvs in the human genome. A, Representation of the human IGH locus (14q32.33) 
and B, of the human IGK locus (2p11.2). Functional genes are boxed and possible 
germ line ancestors for the isolated allergen-specific ScFvs are indicated on top. 
Symbols (Phl p 5-specific: *; Phl p 1-specific: #; Phl p 2-specific: +) represent the 
germ line genes with high sequence identity to the allergen-specific variable regions 
(see Tables E1A and B). The closest germ line genes are indicated with big symbols. 
Gene IGHV3-NL1 on 14q32.33 could not be located with the IMGT/GENE-DB 
software.  
 
FIG. 2. Amino acid sequence alignment of VL regions used in the allergen-specific 
IgE Fabs with the Phl p 1-specific region 25VL. Identical amino acids are indicated by 
dots and complimentarity determining regions (CDR) are highlighted in grey. Amino 
acids involved in the binding of the light chain of the Phl p 2-specific Fab with Phl p 2 
are represented in red.  
 
FIG. 3.  Schematic illustration of the light chain shuffling approach. Allergen-specific 
IgE Fabs (A) were converted into the ScFv format (B). Subsequently the heavy 
chains were recombined with the light chains from the original Fabs (C).  
 
FIG. 4. Detection of complete ScFvs in nitrocellulose-blotted bacterial lysates with an 
anti-E tag antibody. The analysis of a representative number of bacterial clones 
expressing original and shuffled ScFvs (top) is shown. Molecular weight markers 
(kDa) are indicated on the left margin.  
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FIG. 5. Reactivities of ScFvs to a panel of recombinant timothy grass pollen allergens 
(Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, Phl p 12 and Phl p 13) by ELISA. OD 
values (y-axes) corresponding to the binding intensities are shown for the allergens 
(x-axes) and the ScFvs containing heavy chains from IgE Fabs specific for Phl p 5 
(A: 5VH), Phl p 2 (B: 94VH) and Phl p 1 (C: 25VH) (right margins).  
 
FIG. 6. Sensor chip-based studies of the interaction between Phl p 5 and Phl p 5 
specific ScFvs. ScFvs (A: 5VH/5VL; B: 5VH/25VL) were captured on the chip and Phl 
p 5 was injected in 2-fold increasing concentrations from 0.5nM to 16nM (A) or 2nM 
to 64nM (B). Recorded (coloured lines) and calculated curves (black lines) which 
represent fittings of the data to a 1:1 binding model were superimposed. Signal 
intensities (RU) are displayed (y-axes) versus time (s) (x-axes). Association (ka) and 
dissociation (kd) rate constants as well as dissociation constants (KD) are indicated.  
 
Table 1. Summary of ScFvs regarding expression and binding characteristics. ScFvs  
grouped by their heavy chains and combined light chains (top) were classified 
according to expression (E tag detection) and binding to the allergens (bottom) by 
ELISA and Biacore (positive: +; weak: +/-; negative: -). Original clones were 
highlighted in red.  
 
Table 2. Summary of Biacore results for ScFvs with allergen-specificity as 
determined by ELISA. Association (ka) and dissociation (kd) rate constants as well as 
dissociation constants (KD) calculated by fitting the analyzed data with a 1:1 binding 
model are displayed for those ScFvs which could be analyzed by Biacore.  
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FIG. 1B
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FIG. 2
Phl p 1-
specific
Phl p 2-
specific
Phl p 5-
specific
CDR1 CDR2 CDR3
25_LC TQSPSSLSASVGDRVTITCRASQSIGNYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQREDFATYYCQQSNRTPITFGQGTR
43_LC ..........E...........RT.Y...........R..K...H...T..D.............E......G..S...........HG..L...G..T
10_LC .......................TFN......................T.RR.I...........Y.....NG..P...........YS..L...G..K
94_LC .................S.....R.NT......H......K.....................Y............P....S....E.LSASY......K
60_LC .....................R...ST.............K...WS..N................E......N..P....S......YT.LY...P..K
100_LC ......V................G.SSW.A..........K....S.....................S.......P..S.......A.SF.Y......K
5_LC ......V................G.SSW.A..........K....S.....................S.......P..S.......A.SF.Y......K
28_LC .........................LG.............K.......T......................T...PD..........YI..R......K
31_LC .........F...............SS.............K..................................P...........HS..Y......N
14_LC ......................H..S..............K..................................P....N....E.FSPSG......K
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FIG. 4
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FIG. 5
A
B
C
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Ph
l p
1
Ph
l p
2
Ph
l p
5
Ph
l p
6
Ph
l p
7
Ph
l p
12
Ph
l p
13
5VH/5VL
5VH/94VL
5VH/60VL
5VH/100VL
5VH/25VL
5VH/10VL
5VH/43VL
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Ph
l p
1
Ph
l p
2
Ph
l p
5
Ph
l p
6
Ph
l p
7
Ph
l p
12
Ph
l p
13
94VH/94VL
94VH/5VL
94VH/31VL
94VH/14VL
94VH/25VL
94VH/10VL
94VH/43VL
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Ph
l p
1
Ph
l p
2
Ph
l p
5
Ph
l p
6
Ph
l p
7
Ph
l p
12
Ph
l p
13
25VH/25VL
25VH/5VL
25VH/14VL
25VH/28VL
25VH/94VL
25VH/60VL
25VH/100VL
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 98
MANUSCRIPT 2 
 
 
 
FIG. 6
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Methods 
 
Construction of linker DNA for the assembly of VH and VL fragments 
For the construction of linker DNA, 24 separate PCR reactions (Platinum PCR 
Supermix, Invitrogen, Life Technologies, Carlsbad, CA, USA) were performed where 
all possible combinations of the four HJ- and six VL-specific primers 24 were used to 
amplify a DNA sequence coding for a 15 amino acids linker (Gly4Ser)3. 24 linker 
products were purified on a 2% agarose gel, eluted as described, and ligated into the 
pre-cut pSTBlue-1 AccepTor Vector (Novagen) that allows direct ligation of a PCR 
product with 3’-dA overhangs produced by Taq-Polymerase that anneal with 3’-dU on 
the vector. Sequences were confirmed by double-strand sequencing (Microsynth, 
Balgach, Switzerland) performed with the standard T7 and SP6 primers and were 
further used as templates for another PCR step followed by purification as described. 
Concentrations of the 24 separate linkers were determined via Nanodrop (Peqlab, 
Erlangen, Germany) and an equimolar mix was produced.  
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Figure legends 
 
Table E1. Comparison of VH (Table E1A) and VL (Table E1B) sequences from the 
original IgE Fabs with germ line genes (allele *01) from the IMGT database. The 
closest related germ line genes and those with sequence identities with no less than 
5% of the latter are displayed in bold together with their accession numbers and 
nucleotide sequence identities. Likewise, variable (IGHV), diverse (IGHD) and joining 
(IGHJ) genes of heavy chain sequences were identified in Table E1A as well as 
variable (IGKV) and joining (IGKJ) genes of light chain sequences in E1B.  
 
Table E2. Amino acid sequence identities (%) and mean % sequence identities 
between the analyzed VL regions to each other are displayed.  
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Table E1B
Comparison of isolated light chains with germline genes
IGKV1-12*01 96.34% V01577 IGKJ2*01 94.12% J00242
IGKV1D-12*01 95.60% X17263 IGKJ1*01 85.29% J00242
IGKV1D-16*01 91.94% K01323 IGKJ3*01 79.41% J00242
IGKV1-16*01 90.84% J00248 IGKJ4*01 79.41% J00242
IGKV1-9*01 90.48% Z00013 IGKJ5*01 64.71% J00242
IGKV1-39*01 95.70% X59315 IGKJ1*01 96.97% J00242
IGKV1D-39*01 95.70% X59312 IGKJ4*01 78.79% J00242
IGKV1-17*01 89.25% X72808 IGKJ2*01 75.76% J00242
IGKV1-6*01 89.25% M64858 IGKJ3*01 75.76% J00242
IGKV1-NL1*01 89.25% Y14865 IGKJ5*01 66.67% J00242
IGKV1-39*01 93.04% X59315 IGKJ1*01 90.62% J00242
IGKV1D-39*01 93.04% X59312 IGKJ3*01 78.12% J00242
IGKV1-9*01 86.81% Z00013 IGKJ4*01 75.00% J00242
IGKV1-6*01 86.45% M64858 IGKJ2*01 71.88% J00242
IGKV1D-13*01 86.45% X17262 IGKJ5*01 68.75% J00242
IGKV1-39*01 97.49% X59315 IGKJ2*01 94.12% J00242
IGKV1D-39*01 97.49% X59312 IGKJ1*01 73.53% J00242
IGKV1-12*01 91.40% V01577 IGKJ3*01 73.53% J00242
IGKV1-9*01 90.68% Z00013 IGKJ4*01 73.53% J00242
IGKV1D-12*01 90.68% X17263 IGKJ5*01 73.53% J00242
IGKV1-39*01 93.77% X59315 IGKJ2*01 94.87% J00242
IGKV1D-39*01 93.77% X59312 IGKJ1*01 84.21% J00242
IGKV1-12*01 88.64% V01577 IGKJ4*01 84.21% J00242
IGKV1-9*01 88.64% Z00013 IGKJ3*01 81.58% J00242
IGKV1-17*01 88.28% X72808 IGKJ5*01 71.05% J00242
IGKV1-39*01 92.67% X59315 IGKJ3*01 86.84% J00242
IGKV1D-39*01 92.67% X59312 IGKJ2*01 82.05% J00242
IGKV1-12*01 86.81% V01577 IGKJ1*01 76.32% J00242
IGKV1-37*01 86.81% X59316 IGKJ4*01 73.68% J00242
IGKV1D-37*01 86.81% X71893 IGKJ5*01 73.68% J00242
IGKV1-12*01 95.97% V01577 IGKJ2*01 94.74% J00242
IGKV1D-12*01 95.24% X17263 IGKJ1*01 86.84% J00242
IGKV1D-16*01 91.58% K01323 IGKJ3*01 81.58% J00242
IGKV1-16*01 90.48% J00248 IGKJ4*01 81.58% J00242
IGKV1-9*01 90.11% Z00013 IGKJ5*01 68.42% J00242
IGKV1-39*01 95.24% X59315 IGKJ5*01 97.37% J00242
IGKV1D-39*01 95.24% X59312 IGKJ2*01 71.05% J00242
IGKV1-12*01 90.11% V01577 IGKJ4*01 71.05% J00242
IGKV1-17*01 89.38% X72808 IGKJ1*01 68.42% J00242
IGKV1D-12*01 89.38% X17263 IGKJ3*01 68.42% J00242
IGKV1-39*01 90.32% X59315 IGKJ4*01 89.47% J00242
IGKV1D-39*01 90.32% X59312 IGKJ2*01 76.32% J00242
IGKV1-17*01 85.66% X72808 IGKJ3*01 76.32% J00242
IGKV1-9*01 85.66% Z00013 IGKJ1*01 73.68% J00242
IGKV1-12*01 84.95% V01577 IGKJ5*01 65.79% J00242
IGKV1-39*01 91.76% X59315 IGKJ4*01 97.37% J00242
IGKV1D-39*01 91.76% X59312 IGKJ1*01 81.58% J00242
IGKV1-12*01 86.38% V01577 IGKJ3*01 81.58% J00242
IGKV1-27*01 86.02% X63398 IGKJ2*01 78.95% J00242
IGKV1-9*01 86.02% Z00013 IGKJ5*01 71.05% J00242
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Table E2
Amino acid sequence identities (%) and mean % sequence identities between the analyzed VL regions
to each other
25VL 43VL 10VL mean 94VL 60VL 100VL mean 5AVL 28VL 31VL 14VL mean
25VL 100%
43VL 82% 100%
10VL 83% 83% 100%
94VL 83% 75% 78% 100%
60VL 82% 79% 79% 82% 100%
100VL 83% 74% 76% 81% 80% 100%
5AVL 83% 74% 76% 81% 80% 100% 100%
28VL 88% 81% 84% 83% 84% 82% 82% 100%
31VL 90% 82% 82% 86% 85% 87% 87% 89% 100%
14VL 87% 79% 80% 88% 83% 83% 83% 86% 89% 100%
85.2% 86.0%Phl p 5-specific
Phl p 1-specific
82.7%
78.8%
82.2%
Phl p 2-specific Phl p 5-specific
Phl p 1-
specific
Phl p 2-
specific 81.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105
MANUSCRIPT 2 
 106
MANUSCRIPT 3 
 
 
A single chain fragment specific for group 2 grass pollen allergens 
with therapeutic potential 
 
 
 
Elisabeth Gadermaier, Sabine Flicker, Katharina Blatt, Peter Valent, Rudolf Valenta 
 
 
 
 
 
Submitted. 
 
 107
MANUSCRIPT 3 
 108
 
MANUSCRIPT 3 
 
A single chain fragment specific for group 2 grass pollen allergens 
with therapeutic potential 
 
 
Elisabeth Gadermaier, MSc, (a), Sabine Flicker, PhD, (a), Katharina Blatt, (b), Peter 
Valent, MD, (b), Rudolf Valenta, MD, (a, c).  
 
(a) Division of Immunopathology, Department of Pathophysiology and Allergy 
Research, Centre for Pathophysiology, Infectiology and Immunology, Medical 
University of Vienna, Vienna General Hospital, Vienna, Austria. 
(b) Division of Hematology and Hemostaseology, Department of Internal Medicine I, 
Medical University of Vienna, Vienna General Hospital, Vienna, Austria. 
(c) Christian Doppler Laboratory for Allergy Research, Division of Immunopathology,  
Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, 
Infectiology and Immunology, Medical University of Vienna, Vienna General Hospital, 
Vienna, Austria. 
 
Correspondence to: 
Rudolf Valenta, MD 
Division of Immunopathology 
Department of Pathophysiology and Allergy Research 
Centre for Pathophysiology, Infectiology and Immunology 
Medical University of Vienna, Vienna General Hospital 
Währinger Gürtel 18-20, A-1090 Vienna, Austria 
Tel.: +43-1-40400-5108 
 109
MANUSCRIPT 3 
Fax: +43-1-40400-5130 
e-mail: rudolf.valenta@meduniwien.ac.at 
 
Supported by grant P233-B11 and by the special research program F46 of the 
Austria Science Fund (FWF), by the Christian Doppler research Association and a 
research grant from Biomay, Vienna, Austria. 
 
Capsule summary: We characterized a recombinant single chain fragment specific 
for major group 2 grass pollen allergens which inhibits IgE binding to the allergen and 
allergen-induced basophil activation and hence has therapeutic potential.    
 
Key words: Allergy, grass pollen, recombinant single chain fragment, therapy.  
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To the Editor: 
Grass pollen is one of the most frequent and potent allergen sources worldwide 
affecting almost 50% of allergic patients 1. Allergen-specific immunotherapy (SIT) is a 
clinically effective, disease-modifying treatment for grass pollen allergy and has long 
lasting effects 2. However, it has been demonstrated that current allergen-extract-
based SIT induces protective IgG responses mainly against group 1 and group 5 
allergens but not sufficiently against group 2 allergens which represent major 
allergens for more than 60% of grass pollen allergic patients 3, 4. Moreover, it has 
been demonstrated in clinical studies that the group 2 allergen from timothy grass 
pollen, Phl p 2, is besides Phl p 5 the most potent allergen in eliciting immediate type 
skin and respiratory symptoms 5, 6.  
Using combinatorial cloning technology we have identified a Phl p 2-specific IgE Fab 
which after conversion into a full human IgG1 antibody inhibited allergic patients IgE 
binding to Phl p 2 and Phl p 2-induced basophil activation and therefore may be 
useful for treating patients allergic to group 2 grass pollen allergens by passive 
immunization 7. However, in the case of grass pollen allergy the major manifestations 
of the disease are allergic rhinitis, conjunctivitis and asthma for which topical forms of 
treatment as needed would be advantageous. For such topical application large 
amounts of antibodies which are easy and inexpensive to produce and which should 
have low immunogenicity would be needed. Unfortunately complete antibodies may 
elicit neutralizing antibodies even when they are fully human and their production is 
very expensive because cell culture systems are needed 8. In order to decrease 
immunogenicity it has therefore been suggested to use antibody fragments (i.e., 
Fabs) for therapeutic purposes 8. 
Here we report the expression, purification and characterization of a ScFv fragment, 
designated Phl p 2-ScFv that is specific for the major group 2 allergen from timothy 
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grass, Phl p 2. Phl p 2-ScFv could be expressed in the E. coli strain HB2151 as 
soluble ScFv and was purified to homogeneity as a 28 kDa molecule (Fig 1A) by 
affinity chromatography 9. The Phl p 2-ScFv specifically recognized group 2 allergens 
(i.e., Phl p 2) but not other unrelated timothy grass pollen allergens (e.g. Phl p 1, Phl 
p 5, Phl p 6, Phl p 7, Phl p 12, Phl p 13) or the major birch pollen allergen Bet v 1 (Fig 
E1). Importantly, surface plasmon resonance studies revealed a similar association 
and dissociation rate constant of the ScFv fragment to Phl p 2 as was found for the 
complete Phl p 2-specific IgG 7 (Association rate constants Ka for Phl p 2-ScFv: 8.41 
* 105 M-1s-1; Phl p 2 IgG: 2.96 * 105 M-1s-1; dissociation rate constants Kd for Phl p 2-
ScFv: 3.26 * 10-5 s-1; Phl p 2 IgG: 3.38 * 10-5 s-1) and demonstrated stable binding to 
Phl p 2 with a half-life of >19 hours (Fig 1B).  
Using a competitive IgE ELISA 10 it is demonstrated that the Phl p 2-ScFv inhibited 
significantly (p<0.05) the binding of grass pollen allergic patients (n=12) IgE to Phl p 
2 yielding a maximal inhibition of up to 71% in certain patients (29.4% mean 
inhibition) (Fig 2A). Perhaps more important, we found that the Phl p 2-ScFv also 
inhibited Phl p 2-induced basophil activation (Fig 2B). Due to the fact that the Phl p 2-
ScFv lacks IgG constant regions, competition of the ScFv with IgE antibodies for their 
binding sites on the allergen must be the mechanism underlying the inhibition of 
basophil activation and not co-crosslinking of IgE and IgG receptors 11.  
The Phl p 2-ScFv may now be manufactured under conditions of good manufacture 
practice for clinical trials investigating whether topical application to the eyes and 
respiratory tract can inhibit group 2 allergen-induced allergic symptoms. Should the 
clinical trials show efficacy it may be considered as an ad on local therapy for grass 
pollen allergic patients who are sensitized to group 2 allergens.   
 
Elisabeth Gadermaier, MSc a 
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Figure legends 
 
FIG 1. A, Coomassie blue-stained SDS-PAGE. Lane M: Protein molecular mass 
marker (M) (kDa) and lane 1, purified Phl p 2-ScFv. B, Sensor chip-based studies of 
the interaction between Phl p 2 and the Phl p 2-ScFv. Two-fold increasing 
concentrations (0.125 nM – 4 nM) of the ScFv were injected into the flow cell 
containing immobilized Phl p 2. Recorded (coloured) and calculated curves (black) 
which represent a fitting of the response data to a 1:1 interaction model were 
superimposed. Signal intensities (RU) are shown (y-axis) versus the time (s) (x-axis). 
Association (Ka) and dissociation rate constants (Kd) are indicated. 
 
FIG 2. A, Patients’ IgE binding (OD values: y-axis) to plate-bound Phl p 2 after pre-
incubation with bacterial lysates containing the Phl p 2-ScFv or an unrelated ScFv is 
shown, the mean inhibition is indicated. The p-value of <0.05 is displayed. B, A blood 
sample from a Phl p 2-allergic patient was exposed to increasing doses of Phl p 2 (x-
axis) that had been pre-incubated with the Phl p 2-ScFv or an unrelated ScFv. 
CD203c expression on basophils was determined by FACS analysis and is displayed 
as stimulation index on the y-axis. 
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Figure legends 
 
FIG E1. Determination of binding specificities of the Phl p 2-ScFv (OD-values: y-axis) 
to seven timothy grass pollen allergens (Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, Phl 
p 12, Phl p 13) and to the unrelated birch pollen allergen Bet v 1 as control. 
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Passive Immunization with Allergen-Specific
Antibodies
Sabine Flicker, Elisabeth Gadermaier, Christoph Madritsch
and Rudolf Valenta
Abstract The induction of allergen-specific IgG antibodies has been identified as
a major mechanism responsible for the reduction of allergic inflammation in
allergic patients treated by allergen-specific immunotherapy. Several studies
suggest that allergen-specific IgG antibodies induced by vaccination with allergens
block mast cell and basophil degranulation, IgE-facilitated allergen presentation to
T cells and IgE production. The availability of recombinant allergens and tech-
nologies for the production of recombinant human antibodies allows engineering
of allergen-specific antibodies which can be used for passive immunization
(i.e., therapy) and eventually for the prevention of allergy (i.e., prophylaxis).
This chapter summarizes data supporting the possible use of allergen-specific
antibodies for treatment and prophylaxis. Finally, concrete approaches for the
treatment and prevention of allergy based on blocking antibodies are envisioned.
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1 Background
The usefulness of IgG antibodies for passive immunization was demonstrated for
the first time nearly 120 years ago. Passive immunization was applied to treat
different infectious diseases, e.g., rabies, diphtheria and tetanus (von Behring and
Kitasato 1991) (Sawyer 2000). Using the technology of passive serum transfer
developed by Prausnitz and Kuestner (1921) for investigating mechanisms of
allergic inflammation, Cooke et al. discovered that allergen-specific IgG antibodies
that were induced by specific immunotherapy (SIT) were able to inhibit immediate
inflammatory responses. In fact, they could demonstrate that allergen-specific IgG
antibodies which block allergen-induced immediate allergic inflammation were
transferable by simple serum injections from a treated to an untreated patient
(Cooke 1935).
Even before it became technically possible to produce large amounts of defined
allergen-specific IgG antibodies, a few studies provided evidence for the feasibility
of using allergen-specific IgG antibodies for passive immunization. It was dem-
onstrated for immunotherapy with ragweed extract that higher allergen doses were
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tolerated by patients who received combined passive and active immunotherapy
(Bernstein et al. 1979). In order to prevent side effects, bee venom-allergic patients
were pre-treated with beekeeper gammaglobulin to accept higher doses of venom
(Muller et al. 1986; Bousquet et al. 1987).
The analysis of mechanisms underlying SIT with natural allergen extracts has
been facilitated by the availability of recombinant allergens and defined epitopes.
Moreover, several immunotherapy studies have been conducted with purified
recombinant allergens, allergen-derived peptides and genetically modified aller-
gens allowing a better understanding of the importance of blocking antibodies for
successful treatment (Valenta et al. 2010; Larche et al. 2006).
2 Beneficial Role of Allergen-Specific Blocking IgG Antibodies
Allergen-specific IgG antibodies may suppress allergic immune responses and
allergic inflammation through at least three different modes of action which are
summarized in Fig. 1. First, they can inhibit immediate allergic inflammation by
competing with mast cell-bound IgE antibodies for allergen binding and thus
inhibit effector cell degranulation. A beneficial effect (i.e., reduction of degranu-
lation) may be also achieved by co-cross-linking of mast cell-bound IgE and IgG
by allergens (Fig. 1a). Second, allergen-specific IgG antibodies can compete with
IgE bound to antigen presenting cells (APC) and thus prevent IgE-facilitated
allergen presentation to T cells and thus T cell activation (Fig. 1b). Finally,
allergen-specific IgG may capture allergens before they can induce IgE production
(Fig. 1c) (Flicker and Valenta 2003; Wachholz and Durham 2004; Larche
et al. 2006).
Cross-linking of allergens by FceRI-bound IgE on mast cells or basophils is a
key event in allergic inflammation. During the last decades it has been repeatedly
shown by several clinical studies that SIT-induced allergen-specific IgG antibodies
suppress allergen-induced mast cell degranulation and thus immediate allergic
inflammation (Cooke 1935; Loveless 1940; Niederberger et al. 2004; Jutel et al.
2005; Klimek et al. 2005; Pauli et al. 2008; Purohit et al. 2008). IgG antibodies
induced by SIT with a particular allergen source or allergen may also cross-protect
against cross-reactive allergens. In this context it has been found that immuno-
therapy with birch pollen extract also protects against allergy to hazel and alder
pollen (Petersen et al. 1988). More recently, it has been demonstrated that IgG
induced by SIT with recombinant hypoallergenic derivatives of the major birch
pollen allergen Bet v 1 inhibited basophil degranulation by Bet v 1-related food
allergens (Niederberger et al. 2007a). Interestingly, SIT-induced IgG antibodies do
not need to recognize exactly the same epitopes as those which are recognized by
IgE. In fact, it has been shown that also IgG induced against new epitopes can
block IgE binding as long as these antibodies occupy parts of the IgE epitopes or
cause steric inhibition of IgE binding (Pree et al. 2007; Gadermaier et al. 2010a).
It should be also stated at this point that the ability of a ‘‘blocking antibody’’ to
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Fig. 1 Summary of the beneficial roles of allergen-specific blocking IgG antibodies. a Allergen-
specific IgG captures allergen before it can cross-link mast cell-bound IgE and thus suppresses
immediate allergic inflammation. b Allergen-specific IgG prevents allergens from being
presented by IgE-facilitated antigen presentation to T cells and thus reduces T cell activation.
c Allergen-specific IgG binds allergen and thus prevents allergens to activate IgE-producing cells
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compete with IgE for allergen recognition does not at all depend on its isotype or
subclass but only depends on its epitope specificity, affinity and titer. The latter
statement is supported by defined mechanistic experiments performed with puri-
fied antibodies and allergens and cultured effector cells (Table 1). For example,
defined human monoclonal allergen-specific IgG antibodies gained by hybridoma
techniques or combinatorial library technology have been shown to inhibit IgE
from binding to allergens and to suppress allergen-induced basophil degranulation
(Visco et al. 1996; Flicker et al. 2002; Jylha et al. 2009; Padavattan et al. 2009).
However, there is also evidence for another protective effect of allergen-specific
IgG. It has been reported that concomitant binding of IgG and IgE antibodies to the
same allergen may down-regulate effector cell responses through co-cross-linking
of IgE and IgG receptors (Malbec and Daeron 2007; Mertsching et al. 2008).
These studies have been performed mainly in murine models whereas for human
immunotherapy studies no evidence for down-regulation of effector cell activation
by co-cross-linking has been found so far (Ejrnaes et al. 2006).
Moreover, allergen-specific IgG antibodies are responsible for the reduction of
IgE-facilitated antigen presentation by preventing the binding of allergen to APC-
bound IgE antibodies resulting in decreased T cell activation. T cell activation is
crucial for the development and perpetuation of the allergic immune response, and
is also directly linked to the late-phase response as well as chronic inflammation of
the airways (Larche et al. 2006).
In 1999, it was demonstrated that IgE-mediated allergen presentation to birch
allergen-specific T cells was inhibited by IgG from sera of birch SIT patients, but
not by IgG from patients who had received grass pollen-specific SIT, suggesting
that an allergen-specific factor in their sera inhibited the IgE-mediated allergen
presentation (van Neerven et al. 1999). The inhibitory effect was shown to be
present in the IgG fraction of the birch SIT sera. This study and a follow-up study
of sera from a placebo-controlled birch SIT study demonstrated that 100- to 1,000-
fold higher allergen doses are needed to activate birch allergen-specific T cells
after SIT (van Neerven et al. 2004). Confirmation came from another study
demonstrating that blocking of allergen-IgE binding to B cells was mediated
through IgG antibodies that were induced through grass pollen SIT and more
recently by SIT with recombinant hypoallergenic Bet v 1 derivatives (Wachholz
et al. 2003; Pree et al. 2010).
Table 1 Essential features for protective antibodies
Feature References
Epitope specificity and titer Flicker and Valenta (2003), Flicker et al. (2009)
Cross-reactivity Valenta et al. (1996), Gieras et al. (2011)
Affinity Jakobsen et al. (2004, 2005), Padavattan et al. (2009),
Gieras et al. (2011)
Half-life and clearance Akilesh et al. (2007), Jeffris (2009)
Binding to Fc receptors Malbec and Daeron (2007)
Safety Presta (2006), Hansel et al. (2010)
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Thirdly, it has been shown that the induction of allergen-specific IgG antibodies
by SIT is associated with a suppression of the boost of secondary IgE production
by allergen contact. It is well-established that allergic patients exhibit strong
increases of allergen-specific IgE levels after seasonal allergen exposure
(Henderson et al. 1975; Niederberger et al. 2007b). A suppression of the rise of
allergen-specific IgE during the pollen season in patients after SIT was noted in
several studies (Mothes et al. 2003; Niederberger et al. 2004; Creticos et al. 2006).
Since allergen-specific IgG decline relatively quickly after discontinuation of SIT
it has been speculated that the suppression of IgE boosts by several courses of SIT
administered for two or more years may be responsible for the long-term effect of
SIT after its discontinuation (Gadermaier et al. 2011).
3 Isolation and Characterization of Allergen-Specific
IgG Antibodies for Therapy and Prevention
The availability of recombinant purified major allergens of high clinical relevance
provides a solid basis for the application of technologies for the isolation, char-
acterization and production of allergen-specific therapeutic antibodies (Valenta
and Kraft 1995, 2002). Phage display, combinatorial libraries and hybridoma
techniques have enhanced our ability to obtain monoclonal recombinant antibodies
(Huse et al. 1989; McCafferty et al. 1990; Winter et al. 1994).
One strategy to obtain ‘‘blocking antibodies or antibody derivatives’’ is to
isolate IgE antibody fragments–scFvs or IgE Fabs– from allergic patients
(Steinberger et al. 1996; Flicker et al. 2002; Jylha et al. 2009). Due to the lack of
the constant region, these fragments cannot bind to the FceRs and hence do not
elicit IgE-mediated effects. Another strategy is to generate IgE antibody fragments
and convert them into complete human IgG antibodies by engineering the IgE
variable region onto an IgG constant region. These antibodies combine two
important characteristics that may be relevant. They may block IgE binding to the
allergen and in addition may bind to FccRs thus mediating co-cross-linking and
silencing of effector cells or allergen uptake and clearance.
One example for a conversion of an allergen-specific IgE Fab into an IgG1 anti-
body is an IgE Fab specific for grass pollen allergen Phl p 2 obtained by combinatorial
cloning from an allergic patient. This antibody inhibited patients’ IgE binding to Phl
p 2 and Phl p 2-induced histamine release from basophils of grass pollen allergic
patients (Flicker et al. 2002; Padavattan et al. 2009). Nevertheless, it has been
observed that single IgG antibodies that were derived from allergic patients IgE did
not block polyclonal IgE binding to the allergen (Flicker et al. 2000, 2006).
Another possibility for obtaining allergen-specific monoclonal antibodies is
conventional cell cloning technology. For example, monoclonal allergen-specific
IgG antibodies have been isolated by EBV-transformation of allergen-specific B
cells of a SIT-treated patient (Visco et al. 1996; Lebecque et al. 1997; Denepoux
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et al. 2000). However, as yet no human cell line producing allergen-specific IgE
has been described.
Some essential features of allergen-specific IgG antibodies with protective
potential are summarized in Table 1. The probably most important properties that
make an IgG antibody a protective IgG antibody are epitope specificity and titer.
3.1 Epitope Specificity and Titer
It has been demonstrated that the blocking capacity of an allergen-specific anti-
body depends on its ability to occupy IgE binding sites or to bind in close vicinity
so that there is steric hindrance of IgE binding (Flicker and Valenta 2003; Gieras
et al. 2011).
In fact, SIT with allergen extracts can induce a large variety of IgG antibodies
of which certain often do not even react with allergens, others recognize allergens
but do not inhibit IgE binding and only some block IgE recognition (Flicker and
Valenta 2003). Since SIT also induces ‘‘useless’’ IgG responses it has not been
possible to associate the induction of IgG antibodies directly with clinical
improvement (Djurup and Malling 1987; Birkner et al. 1990; Bodtger et al. 2005).
Allergen-specific IgG antibodies which do not inhibit IgE binding to the allergen
(Flicker et al. 2008) have been described and there is even evidence for IgG
antibodies which may enhance IgE binding to allergens (Denepoux et al. 2000).
Both reports clearly demonstrate that there are non-blocking IgG recognizing the
wrong epitopes and it is not surprising that such antibodies have no therapeutic
effect even when they are present in molar excess. The latter may also explain why
certain allergic patients mount large amounts of allergen-specific IgG antibody
responses but nevertheless suffer from allergy. Thus simple measurements of the
allergen-specific IgG antibodies will not be sufficient surrogate markers for the
clinical outcome of SIT.
However, if allergen-specific IgG antibodies have the correct epitope specificity
and can inhibit IgE binding to the allergen, their protective effect will be greater if
their concentration and titer is high.
It has been claimed that mainly allergen-specific IgG4 antibodies are responsible
for therapeutic effects during SIT (Aalberse et al. 1983). However, several studies
demonstrate that the blocking activity of therapy-induced IgG antibodies does not
reside exclusively in the IgG4 fraction. Blocking antibodies of the IgG1 subclass
have been described (Visco et al. 1996; Flicker et al. 2002) and it has been shown
that IgG4-depleted sera retained their blocking activity (Ejrnaes et al. 2004).
Interestingly, it has turned out that the vast majority of allergens contain con-
formational IgE epitopes which are difficult to characterize because this requires
sophisticated technologies e.g., three-dimensional structure analysis. With the
application of structural biology methods first structures of complexes consisting
of allergens and specific antibodies have been solved. The birch pollen allergen,
Bet v 1, the bee venom allergen, Api m 2 (hyaluronidase) and the cockroach
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allergen Bla g 2, were co-crystallized with recombinant mouse IgG Fabs
(Mirza et al. 2000; Padavattan et al. 2007; Li et al. 2008). Furthermore, the major
bovine milk allergen, b-lactoglobulin and the major grass pollen allergen Phl p 2
were crystallized in complexes with recombinant human IgE Fabs (Niemi et al.
2007; Padavattan et al. 2009). These allergen-antibody complexes gave us for the
first time insight in the molecular interaction between allergen and antibodies and
revealed the nature of conformational IgE epitopes (Niemi et al. 2007; Padavattan
et al. 2009).
3.2 Cross-Reactivity
Another important feature of an allergen-specific protective antibody is its cross-
reactivity to homologous allergens present in related species. This finding is of
great importance because IgE antibodies from allergic patients often displayed
cross-reactivity to allergens from other allergen sources (Valenta et al. 1996;
Radauer et al. 2008). So far, several monoclonal human and murine IgG blocking
antibodies were demonstrated to cross-react with homologous allergens from
related species (Visco et al. 1996; Lebecque et al. 1997; Flicker et al. 2002; Gieras
et al. 2011) and were even shown to inhibit patients’ IgE to related allergens
(Gieras et al. 2011).
3.3 Affinity
Aside from epitope specificity, the affinity of antibodies for the given epitopes is an
important factor. Affinity is perceived as the strength of binding and can be cal-
culated from the quotient of dissociation rate and association rate. Moreover, the
kinetics of an antibody/allergen complex is of great importance because the kinetics
determines the on and off rates of formed complexes. Nowadays, the determination
of the affinity and the kinetics of such complexes can be assessed by surface
plasmon resonance (SPR) (Padavattan et al. 2009). When targeting protective
antibodies applicable for passive immunotherapy high-affinity and low-dissociation
rates are preferable. Determinations by SPR revealed that Bet v 1-specific IgG
antibodies gained from allergic patients who had undergone immunotherapy had
high affinities recorded in the nM range and hence reside in the same range as Bet v
1-specific IgE gained from the same patient (Jakobsen et al. 2004, 2005).
Recently, a human monoclonal IgG antibody specific for the major grass pollen
allergen Phl p 2 has been engineered by grafting the variable domain of the
corresponding IgE onto the human IgG1 constant region. This antibody showed an
extremely high affinity to Phl p 2 and strongly inhibited allergic patients IgE
binding to the allergen as well as allergen-induced basophil degranulation
(Padavattan et al. 2009). Murine antibodies recognizing peptides derived from the
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major IgE binding site of the major birch pollen allergen, Bet v 1 also showed high
affinity to Bet v 1 (Gieras et al. 2011). Interestingly, these antibodies inhibited
patients IgE binding but were less potent in inhibiting allergen-induced basophil
degranulation.
The pairing of heavy and light chains also has an influence on the affinity and
specificity of an antibody. Affinity of antibodies can be modified by pairing the
original VH sequence with different VL sequences. Kim and Hong reported about
an enhancement of affinity of a humanized monoclonal antibody after light chain
shuffling (Kim and Hong 2007). For allergen-specific human IgE antibodies there
is some evidence that the heavy chain determines allergen-specificity (Laffer et al.
2001; Rojas et al. 2004; Christensen et al. 2009; Gadermaier et al. 2010b). It is
therefore quite possible, that the affinity of allergen-specific antibodies can be
increased by shuffling of light chains.
3.4 Half-Life and Clearance
The affinity of a therapeutic allergen-specific antibody is not only important for the
effective blocking of IgE but also affects other parameters. For example, high
affinity of a therapeutic antibody would decrease dosing and frequency of
administration, and thus reduce costs of treatment. Several reports describe
different methods for improving affinity constants of antibodies toward their
antigens. It could be shown that error-prone PCR using an excess of guanine and/
or thymine resulted in the retrieval of antibody fragments with significantly
improved binding affinities for the corresponding antigen (Persson et al. 2008).
The same authors demonstrated in a former study that the change of several
residues situated in the paratope of an antibody was critical for the strength of the
binding affinity (Persson et al. 2006). Aside from the random mutagenesis strategy
another method called ‘‘codon-based mutagenesis’’ has been described. The
principle of this targeted approach is that specifically the CDRs are mutated
(Glaser et al. 1992). Utilizing this technique Wu et al. succeeded in improving the
affinity of an anti-angiogenic antibody by greater than 90-fold (Wu et al. 1998).
It turned out that targeted mutagenesis in the CDR 3 led to the greatest affinity
improvements due to the diminished off rate of the antibodies (Finlay et al. 2009).
Besides the efforts to improve the affinity constants of antibodies for the given
antigen, many studies focus on understanding the factors that affect the phar-
macokinectics of monoclonal antibodies, a field that is summarized by the term Fc
engineering. The goal is the protection of monoclonal IgG antibodies from rapid
clearance from the body, a prerequisite for effective passive immunization. Much
effort has been made to prolong the survival of applied IgG including protection of
antibody degradation through binding to Fc-receptors, e.g., neonatal Fc receptor
(FcRn) and Fcc receptors (FccR). Several studies describe IgG stabilization by
FcRn to their serum persistence by recycling internalized IgG to the cell surface
(Ghetie et al. 1996; Akilesh et al. 2007; Roopenian and Akilesh 2007). In this
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context it turned out that human IgG1, IgG2 and IgG4 per se exhibit longer
elimination half-lives than IgG3 a fact that is attributed to the binding differences
to FcRn, as result of a single amino acid difference in the FcRn binding domain
(Ghetie and Ward 2002). In accordance, attempts to alter the human IgG1 antibody
sequences, i.e., a single mutation in the CH2–CH3 region of the Fc part, led to
affinity improvement of the human FcRn which was shown by Biacore analysis but
also by in vivo studies in cynomogulus monkeys (Yeung et al. 2009). Neverthe-
less, the authors admitted that the increase of the affinity is not always associated
with lower clearance (Yeung et al. 2009). Besides the cynomogulus monkey model
which is well-known to be appropriate for investigating the half-lives of human
IgG antibodies because the monkey FcRn binds human IgG, a human FcRn
transgenic mouse model has been developed to evaluate the pre-clinical pharma-
cokinetics of human therapeutic antibodies (Petkova et al. 2006).
Another emerging issue is that the kind of glycosylation, e.g., galactose, fucose,
N-acetylglucosamine has a strong impact on the half-life of the antibody (Jefferis
2009a). Different glycosylation patterns were easily achieved by using different
expression systems (mammalian cells, yeasts, plants, insect cells and prokaryotes).
The most widely used production cell lines for human therapeutic IgG antibodies are
currently mammalian cells because the glycosylation pattern of assembled anti-
bodies almost resembles the naturally glycosylated antibodies. Nevertheless,
recombinant antibodies produced in well-established hamster or mouse cell lines
like CHO, NSO and Sp2/0 usually have small quantities of unnatural glycoforms
bearing the risk to be immunogenic and thus be cleared quicker by forming immune
complexes (Jefferis 2009b). Therefore first efforts have been made to create
genetically modified CHO cells or as alternative, yeast lines that use human
enzymes for glycosylation to produce recombinant glycosylated human IgG anti-
bodies with high-structural fidelity with the natural IgG antibodies (Jefferis 2009b).
The route of antibody application e.g., topical administration or systemic
treatment is also discussed to influence the in vivo half-life of antibodies. It turned
out that antibody titers in the BAL fluid of naïve BALB/C mice 48 h after
intranasal instillation are hardly detectable whereas antibodies administered by i.v.
route are maintained for several months in the sera (Sehra et al. 2003).
It is further reported that complete IgG antibodies in general are beneficial
compared to antibody fragments like scFvs or Fabs due to their extended half-lives
(Presta 2008). However, if neutralizing antibodies without eliciting any Fc-mediated
effects are in favor antibody fragments became again of interest despite their short
half-life. Several attempts have been made to prolong serum half-life of antibody
fragments including linkage to polyethylene glycol (PEGylation) (Chapman et al.
1999; Constantinou et al. 2010) or linkage to albumin (Constantinou et al. 2010).
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3.5 Binding to Fc Receptors
An interesting question is whether allergen-specific IgG antibodies besides simply
competing for epitopes on allergens may exert their beneficial roles also via
binding to FccR.
In this context, it has been shown in OVA-sensitized mice that complete
OVA-specific IgG2a and not OVA-specific F(ab)2 suppressed inflammation indi-
cating that FccR-mediated mechanisms may be responsible for the repression
(Sehra et al. 2003). FACS analysis clearly showed that alveolar macrophages are
the main population responsible for the OVA capture by binding to IgG and FccR
on these cells. In parallel, a two-fold increase in INF-c-secreting T cells was
observed in IgG-treated mice (Sehra et al. 2003). However, it is also possible that
complete antibodies were more efficient simply due to their longer half-life.
Strait et al. obtained results in a murine model suggesting that besides allergen
interception by IgG antibodies (i.e., FccR-mediated cellular uptake of allergen)
also cross-linking of FceRI to the inhibitory FccRIIb through the allergen/IgG/IgE
complex contributes to the inhibitory effect of administered IgG antibodies. They
concluded that FceRI/FccRIIb cross-linking makes an important contribution when
blocking IgG levels are limited but is redundant when blocking IgG antibody
concentrations are high relative to concentrations of antigen in mice (Strait et al.
2006). Another recent report indicated that co-administration of mouse IgE and
mouse IgG prevented mast cell degranulation in BALB/c mice whereas no IgG-
dependent inhibition of mast cell degranulation was observed in FccRIIB-/- mice
(Uermosi et al. 2010).
For the human system, there is relatively little evidence that cross-linking of the
FceRI to the inhibitory IgG receptor FccRIIb indeed plays a role in inhibiting
histamine release. There are data from cultured human mast cells and basophils
(Zhu et al. 2002; Tam et al. 2004; Zhang et al. 2004) and from in vivo studies
using transgenic mice expressing human FceRa (Allen et al. 2007). By investi-
gating the inhibitory role of FccRIIb of cat allergic patients who have received
SIT, Cady et al. found evidence that FccRIIA may be involved in the inhibition of
basophil activation (Cady et al. 2010).
However, the investigation of the potential role of FccR co-cross-linking in
reducing allergen sensitivity in patients receiving immunotherapy failed to provide
any evidence for this mechanism in allergic patients (Ejrnaes et al. 2006).
The choice of the isotype/subclass of a therapeutic allergen-specific antibody
may be driven by several considerations. IgG1 antibodies are often used as
therapeutic antibodies. They have a long in vivo half-life but have been proven
to be effective in activation of ADCC and complement activation (Jefferis 2007).
Both are certainly not desired features although allergic patients develop aller-
gen-specific IgG1 in the course of SIT without showing signs of inflammation.
Most likely, allergen-specific IgG4 antibodies that just activate FccRI and
FccRIIIa depending on the allotype of the receptor and/or the glycoform of the
IgG4 antibody but do not activate complement represent the most desirable
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subclass for passive immunization against allergens (Jefferis 2007, 2009b).
In fact, allergen-specific IgG4 is the prominent subclass associated with suc-
cessful SIT, does not activate complement and can pass the placental barrier
(Flicker et al. 2009) and thus may eventually protect children from becoming
sensitized.
3.6 Safety of Recombinant Monoclonal Antibodies
Considerable efforts have been made in the last years to reduce side effects of
therapeutic monoclonal antibodies. Among the side effects, immunogenicity is a
major problem because it may lead to the development of antibodies against
administered antibodies resulting in immune complexes, hypersensitivity or
accelerated clearance of the applied antibodies. For decreasing immunogenicity of
applied non-human antibodies different strategies like humanization, ‘‘resurfac-
ing’’ (only surface-accessible framework amino acids are altered to human ones
while the CDR and buried amino acids remain from parental rodent antibody) or
SDR grafting (only a subset of CDR residues that are involved in binding of the
antibody called ‘‘specificity-determining regions’’ is altered) have been suggested
(Presta 2006). De-immunization, another technology, means the identification and
alteration of potential T cell epitopes present in the antibody without reducing the
binding affinity (Presta 2006). The availability of fully human monoclonal anti-
bodies by phage display library or transgenic mice is another possibility to produce
therapeutic antibodies with low immunogenicity. To date, just few examples of
human therapeutic antibodies exist that have passed the safety requirements
(FDA approval) and are already used in the field of oncology, psoriasis and asthma
(Corren et al. 2010; Hansel et al. 2010). The lessons learned from the other fields
may be translated to the field of type I allergy.
4 Proof of Concept Testing in Animal Models
In order to investigate the in vivo efficacy of passive administration of allergen-
specific IgG antibodies a few murine models have been established so far. It has
been shown that topical or systemic administration of allergen-specific IgG anti-
bodies reduces allergic inflammation in sensitized mice (Sehra et al. 2003; Moerch
et al. 2006; Strait et al. 2006) (Flicker unpublished data). Sera of OVA-sensitized
mice that received anti-OVA specific IgG antibodies exhibited significantly
reduced OVA-specific IgE levels, significantly reduced levels of leukocytes and
eosinophil granulocytes in BALs and significantly reduced AHR to methacholine
(Sehra et al. 2003; Moerch et al. 2006). The efficacy of a single administration of
allergen-specific IgG antibodies was confirmed by data from mice sensitized to
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three of the most important seasonal allergens, the major grass and birch pollen
allergens, Phl p 1, Phl p 5 and Bet v 1 (Flicker unpublished data).
Very few data exist so far for prophylactic treatment with allergen-specific
antibodies, i.e., administration of allergen-specific antibodies before sensitization
to allergen takes place. It has already been demonstrated in experimental animal
models and in clinical studies that prenatal induction of allergen-specific IgG
antibodies protects against allergen-induced sensitization and allergic inflam-
mation in the offspring (Glovsky et al. 1991; Jenmalm and Bjorksten 2000; Ut-
hoff et al. 2003; Polte and Hansen 2008; Polte et al. 2008; Flicker et al. 2009;
Victor et al. 2010).
It will thus be very interesting to explore if passive immunization of pregnant
mothers or new born children with allergen-specific IgG antibodies can suppress
allergic sensitization (Fig. 2).
5 Possible Application of Allergen-Specific IgG for Therapy
and Prophylaxis
With the availability of defined reagents (i.e., clinically relevant allergens) and
new technologies (e.g., combinatorial cloning technologies and large-scale pro-
duction of fully human antibodies) it should be possible to produce allergen-
specific human IgG antibodies for the clinically most relevant allergens. The
following concrete applications for allergen-specific IgG antibodies can be
envisaged. First, it should be possible to treat seasonal allergies by passive
immunization of allergic patients shortly before the beginning of the pollen season
(Fig. 2a). Since human allergen-specific IgG4 antibodies have a half-life of
approximately 21 days it is quite possible that allergic patients can be protected by
a single passive immunization for a full pollen season. Perennial allergies are
perhaps not easy to treat by passive immunization because repeated injections may
be needed, but also Omalizumab, an injected therapeutic anti-IgE is successfully
used to treat such patients (Holgate et al. 2009). It may thus well be envisioned that
(b)(a) (c)
Fig. 2 Envisaged therapeutic and prophylactic immunization with allergen-specific antibod-
ies.a Therapeutic application may protect allergic patients from symptoms in the course of
allergen contact. b Prophylactic application shortly after birth to children may protect against
allergic sensitization. c Application of allergen-specific IgG antibodies to pregnant mother may
lead to diaplacental transfer to children and protect them against allergic sensitization after birth
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passive immunization against allergens which elicit severe asthma attacks may be
an alternative to heavy immunosuppressive treatment.
Another very interesting application of allergen-specific IgG antibodies may be
prophylactic immunization (Fig. 2). There is some evidence that prenatal induc-
tion of allergen-specific IgG antibodies may protect against allergen-induced
sensitization and allergic inflammation in the offspring (Glovsky et al. 1991;
Jenmalm and Bjorksten 2000; Flicker et al. 2009). For prophylaxis, allergen-
specific IgG may be either administered to pregnant women who transmit the
protective IgG via their placenta to the children (Fig. 2c) or directly to the children
shortly after birth in order to prevent allergic sensitization (Fig. 2b).
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ternative approach is the usage of filamentous phage li-
braries that display random sets of peptides. Panning of 
these libraries with the antibody of interest will select 
peptides that are involved in antibody-antigen interac-
tion and that may mimic conformational B cell epitopes.
 The article of Tiwari et al.  [4] in this issue describes the 
mapping of a conformational epitope on the major cock-
roach allergen Bla g 2. This mapping was performed by 
the panning of a 12-mer phage display peptide library (i.e. 
Ph.D. library purchased from the  New England Biolabs) 
with the mAb 7C11  [5] that is described as a surrogate for 
human IgE. For this reason, a modified version of the 
panning protocol was established to select in a more 
stringent way for high-affinity binding phages. Only two 
displayed peptides could be identified that share very 
high degrees of amino acid identities as they differed in 
only one amino acid. The isolated phages displayed pep-
tides with similar specificity and binding strength. Pep-
tides were further matched on the surface of the three-
dimensional structure of Bla g 2 (PDB ID: 1YG9) with the 
help of the computational algorithm EpiSearch. In the 
present study, mapping of the two peptides led to the iso-
lation of four overlapping surface patches that share four 
amino acids. The four patches identified 17 out of 18 ex-
perimentally determined residues; this corresponds to a 
discovery of 94%. The predicted conformational epitope 
 In type I allergy, IgE antibodies directed against spe-
cific epitopes on foreign proteins or glycoproteins are 
produced during the process of sensitization. These IgE 
antibodies are further bound to effector cells like mast 
cells and basophils, and their crosslink through the cor-
responding allergens is essential for the initiation of al-
lergic symptoms. The vast majority of allergens contain 
conformational B cell epitopes, comprising amino acids 
that are in close vicinity only in the folded protein where-
as they are noncontinuous in the linear sequence. Result-
ing from this three-dimensional architecture, conforma-
tional epitopes are difficult to characterize.
 However, it is of great importance for the better under-
standing of immune responses and for the design of ef-
fective active and passive treatment strategies to gain also 
precise knowledge of the interacting surface between IgE 
antibodies and their corresponding epitopes.
 The most direct way of identifying conformational
epitopes is still the determination of the three-dimen-
sional structure of the antibody-allergen complex by X-
ray crystallography  [1, 2] . But there are limitations in the 
performance as the procedure is very time consuming 
and needs a large amount of purified protein complexes. 
Another method is presented in the article of Gieras et al. 
 [3] showing that peptide-specific monoclonal antibodies 
(mAb) can also map conformational IgE epitopes. An al-
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in the current study was finally validated by comparison 
with the genuine epitope presented by the already pub-
lished co-crystal of Bla g 2 and mAb 7C11  [5] .
 The strength of this article is the selection of two pep-
tides that – via the identification of four high scoring 
patches – discovered in the end 94% of all experimen-
tally determined residues. The selection of these peptides 
was performed by a modified phage display screening 
method that included an additional elution step to get rid 
of weakly bound phages as well as a 10-fold reduction step 
in mAb 7C11 concentration from one panning round to 
the next. These very stringent isolation conditions select 
for high-affinity binders, therefore accepting low pan-
ning output. The current approach uses EpiSearch for 
mapping isolated peptides, a program that is described to 
show the advantages of being quite flexible and time-sav-
ing in comparison to other computational algorithms. 
EpiSearch was already applied for epitope mapping in six 
unrelated experimental data sets; in these cases it cor-
rectly mapped the location of conformational epitopes 
and the identified highest scoring patches covered in 
most cases more than 50% of the experimentally deter-
mined residues  [6] . The authors of the current paper 
could even report an improvement in prediction of par-
ticipating amino acid residues compared to the described 
former studies although, quite surprisingly, it was shown 
that the EpiSearch program is able to map 17 out of 18 
amino acids from the genuine epitope with the help of 
two 12-mer peptides.
 Nevertheless, there are also some weak points within 
the paper. The isolated peptides that were described here 
for the very first time were characterized only in their 
phage-bound version. The production of soluble peptides 
would offer tools to precisely study their interaction with 
the specific antibody not only for binding specificity and 
inhibition potential but also for affinity in Biacore analy-
sis. Additionally, it would have been beneficial to isolate 
and map more than the two described peptides. There-
fore, more extensive screening or screening of a more di-
verse library would be essential.
 The identification of conformational epitopes via 
screening of random peptide libraries and further their 
mapping with the use of the EpiSearch program as de-
scribed in this article seem to be useful in terms of defin-
ing their correct localization. These days much effort is 
put on the development of new fast and precise strategies 
dealing with epitope mapping. An example for a recent 
tool is the software SPADE that is the first approach pre-
dicting IgE epitopes by combining structural and cross-
reactivity data and that compared to other prediction 
tools yields highest specificities  [7] .
 However, with currently available technologies, the 
only rational method of identifying all amino acid resi-
dues from a conformational – ‘in shape’ – epitope is mea-
suring the crystal structure of an allergen in complex 
with the corresponding antibody.
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